supplementary materials figures -...

www.sciencemag.org/cgi/content/full/science.aad5788/DC1

Supplementary Materials for

Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak

Zachary A. Bornholdt, Hannah L. Turner, Charles D. Murin, Wen Li, Devin Sok, Colby A. Souders, Ashley E. Piper, Arthur Goff, Joshua D. Shamblin, Suzanne E. Wollen, Thomas R. Sprague, Marnie L. Fusco, Kathleen B. J. Pommert, Lisa A. Cavacini, Heidi L. Smith,

Mark Klempner, Keith A. Reimann, Eric Krauland, Tillman U. Gerngross, Dane K. Wittrup, Erica Ollmann Saphire, Dennis R. Burton, Pamela J. Glass, Andrew B. Ward,

Laura M. Walker*

*Corresponding author. E-mail: [email protected]

Published 18 February 2016 on First Release DOI: 10.1126/science.aad5788

This PDF file includes:

Materials and Methods Figs. S1 to S14 Tables S1 to S7 References (31–39)

Materials and Methods Human subjects

Human blood samples were collected after Institutional Review Board (IRB)-approval of a protocol to isolate B cells from healthy adult volunteers to identify antibodies elicited from prior immunization or infections. Eligible subjects were determined based on immunization and infection history recorded on a self-reported questionnaire completed prior to sample collection.

Peripheral blood mononuclear cells were obtained from a survivor of the 2014 EBOV outbreak three months after the patient had been diagnosed with EBOV infection.

B cell and plasma isolation Approximately 85 ml of whole blood was collected in 8.5 ml ACD Solution A

Vacutainer® venous blood collection tubes (Becton Dickinson) per the manufacturer’s protocol. Blood was transported at room temperature and distributed into 50 ml conical tubes before addition of 300 µl of RosetteSep™ human B cell enrichment cocktail (StemCell Technologies) per 21 ml of blood, mixed by inversion and incubated for 20 minutes at room temperature. The total volume was brought to 50 ml with Hank’s Balanced Salt Solution (HBSS), layered over Ficoll-Paque Plus (GE Healthcare) and centrifuged following the manufacturer’s protocol. The B cell layer was removed from the density gradient by pipette, washed twice in HBSS by centrifugation at 400xg, frozen at 6.5x106 cells/ml in a 1:1 mixture of FBS (Life Technologies) and cryoprotective medium (Lonza) and stored under liquid nitrogen. Plasma was collected from the top layer of the density gradient and stored at -80°C until use.

Anti-EBOV GP plasma ELISA A high-binding ELISA plate was coated with 1 µg/ml of EBOV rGP∆TM (IBT

BioSciences) diluted in PBS overnight at 4°C. After washing, wells were blocked with 1% BSA in PBS and 0.05% Tween-20 for 2 hours at room temperature. Wells were washed and serial dilutions of human plasma (diluted in blocking buffer) were added and incubated for 1.5 hours at room temperature. As positive and negative controls, serial dilutions of mAb KZ52 (IBT BioSciences) or an irrelevant human mAb, respectively, were added to appropriate wells. After washing, HRP-conjugated donkey anti-human IgG (Jackson ImmunoResearch) or HRP-conjugated goat anti-human IgA (Southern Biotech) secondary antibody was incubated in appropriate wells for 1.25 hours at room temperature. Wells were washed twice and developed with SureBlue TMB substrate (KPL). The reaction was stopped with 1M HCl and wells were read on an EMax Microplate Reader (Molecular Devices) at 450nm wavelength. Plasma endpoint titers were determined by calculating the highest serum dilution that gives a reading above the blank including three standard deviations.

Single B cell sorting Purified B cells were stained using anti-human IgM (BV605), IgD (BV605), IgG

(BV421), CD8 (APC-Cy7), CD14 (AF700), CD19 (PerCP-Cy5.5), CD20 (PerCP-Cy5.5)

and biotinylated EBOV GP∆TM. Biotinylated GP∆TM was used at a concentration of 50 nM and detected using streptavidin-APC (Life Technologies) at a dilution of 1:500. Single cells were sorted on a MoFlo cytometer (Beckman-Coulter) into 96-well PCR plates (BioRad) containing 20 µl/well of lysis buffer [5 µl of 5X first strand cDNA buffer (Invitrogen), 0.5 µl RNaseOUT (Invitrogen), 1.25 µl dithiothreitol (Invitrogen), 0.625 µl NP-40 (New England Biolabs), and 12.6 µl dH2O]. Plates were immediately frozen on dry ice before storage at −80°C.

Amplification and cloning of antibody variable genes Single B cell PCR was performed essentially as previously described(31). Briefly,

IgH, Igλ and Igκ variable gene transcripts were amplified by RT-PCR and nested PCR reactions using cocktails of primers specific for IgG(31). The primers used in the second round of PCR contained 40 base pairs of 5’ and 3’ homology to the cut expression vectors to allow for cloning by homologous recombination into Saccharomyces cerevisiae(32). PCR products were cloned into S. cerevisiae using the lithium acetate method for chemical transformation(33). Each transformation reaction contained 20 µl of unpurified heavy chain and light chain PCR product and 200 ng of cut heavy and light chain plasmids. Individual yeast colonies were picked for sequencing and down-stream characterization.

Expression and purification of antibodies and Fab fragments Antibodies used for binding experiments, competition assays, neutralization assays,

and structural studies were expressed in Saccharomyces cerevisiae cultures grown in 24 well plates. After 6 days of growth, the yeast cell culture supernatant was harvested by centrifugation and subject to purification. IgGs used in protection experiments were expressed by transient co-transfection of heavy and light chain plasmids into HEK293 cells. One day prior to transfection, HEK293 cells were passaged at 2.0 - 2.5 X 106 cells/ml. On the day of transfection, cells were pelleted by centrifuging at 400 g for 5 min, and cell pellets were resuspended in fresh FreeStyle F17 medium at a density of 4 X 106 cells/ml and returned to the incubator. A transfection mixture was prepared by first diluting the plasmid DNA preparations in FreeStyle F17 medium (1.33 µg total plasmid DNA per ml of culture). Transfection agent, PEIpro™ (Polyplus Transfection, Illkirch, France), was then added to the diluted DNA at a DNA-to-PEI ratio of 1:2, and the mixture was incubated at room temperature for 10 min. The transfection mixture was then added to the culture. Cultures were harvested six days post transfection by two rounds of centrifugation, each at 2000xg for 5 min, and the clarified conditioned medium subject to antibody purification. Cell supernatents were purified by passing over Protein A agarose (MabSelect SuRe™ from GE Healthcare Life Sciences). The bound antibodies were washed with PBS, eluted with 200 mM acetic acid / 50 mM NaCl pH 3.5 into 1/8th volume 2M Hepes pH 8.0, and buffer-exchanged into PBS pH 7.0. Fabs were generated by digesting the IgGs with papain for 2h at 30°C. The digestion was terminated by the addition of iodoacetamide, and the Fab and Fc mixtures were passed over Protein A agarose to remove Fc fragments and undigested IgG. The flowthrough of the Protein A

resin was then passed over CaptureSelect™ IgG-CH1 affinity resin (ThermoFischer Scientific), and eluted with 200 mM acetic acid / 50 mM NaCl pH 3.5 into 1/8th volume 2M Hepes pH 8.0. Fab fragments then were buffer-exchanged into PBS pH 7.0.

Expression and Purification of EBOV GPs Recombinant EBOV GP ectodomains containing the mucin-like domain (EBOV

GPΔTM) or lacking residues 312–463 of the mucin-like domain (EBOV GPΔmuc) were produced as described previously(6, 27).

EBOV GP∆TM biotinylation EBOV GP∆TM was biotinylated using EZ-Link™ Sulfo-NHS-LC-Biotin (Life

Technologies) followed by a desalting step by a Zeba™ Spin Desalting Column (Life Technologies).

Biolayer Interferometry binding analysis IgG binding to the different GP antigens was determined by BLI measurements

using a FortèBio Octet HTX instrument (Pall Life Sciences). For high-throughput KD screening, IgGs were immobilized on AHQ sensors (Pall Life Sciences) and exposed to 100 nM antigen in PBS containing 0.1% BSA (PBSF) for an association step, followed by a dissociation step in PBSF buffer. Data was analyzed using the ForteBio Data Analysis Software 7. The data was fit to a 1:1 binding model to calculate an association and dissociation rate, and KD was calculated using the ratio kd/ka.

Anti-GP mAb ELISAs ELISA plates were coated with 50 µl PBS containing 4 µg/mL EBOV GP antigens

for 1 h at room temperature. After washing, wells were blocked with 3% BSA for 1 h at room temperature. After removal of the blocking solution, mAbs were applied to the plates at a concentration of 0.2 µg/ml and incubated at room temperature for 1 h. After washing, binding was detected with an anti-human HRP-conjugated secondary antibody and TMB substrate. Optical density was read at 450 nm.

Antibody competition assays Antibody competition assays were performed essentially as previously

described(20). Antibody competition was measured by the ability of a control anti-EBOV GP Fab to inhibit binding of yeast surface-expressed anti-GP IgGs to GP∆muc. 50 nM biotinylated GP∆muc was pre-incubated with 1 µM competitor Fab for 30 min at RT and then added to a suspension of yeast-expressed anti-GP IgG. Unbound antigen was removed by washing with PBSF. After washing, bound antigen was detected using Streptavidin Alexa Fluor 633 at a 1:500 dilution (Life Technologies) and analyzed by flow cytometry using a BD FACS Canto II. Results are expressed as the fold reduction in antigen binding in the presence of competitor Fab relative to an antigen-only control.

Neutralization assays Virus-specific neutralizing antibody responses were titrated essentially as previously

described(34). Briefly, plasma or antibodies were diluted serially in Minimal Essential Medium (Corning Cellgro, Manassas, VA) containing 5% heat-inactivated fetal bovine serum (Gibco-Invitrogen, Gaithersburg, MD), 1X Anti-Anti (Gibco-Invitrogen, Gaithersburg, MD) (MEM complete) and incubated 1 hour at 37°C with virus. After incubation, the antibody-virus or plasma-virus mixture was added in duplicate to 6-well plates containing 90-95% confluent monolayers of Vero E6 cells. Plates were incubated for 1 hour at 37°C with gentle rocking every 15 minutes. Following the incubation, wells were overlaid with 0.5% agarose in supplemented EBME media, 10% heat-inactivated fetal bovine serum (Gibco-Invitrogen, Gaithersburg, MD), 2X Anti-Anti (Gibco-Invitrogen, Gaithersburg, MD), and plates were incubated at 37°C, 5% CO2 for 7 days. On day 7, cells were stained by the addition of a second overlay prepared as above containing 4-5% neutral red. Plates were incubated for 18-24 hours at 37°C, 5% CO2. The endpoint titer was determined to be the highest dilution with a 50% or greater or 80% or greater reduction (PRNT50, PRNT80) in the number of plaques observed in control wells. The assay limit of detection was calculated to be 5 plaque forming units (p.f.u.)/ml by this method.

Single-particle electron microscopy For all EM studies the EBOV GP∆TM construct described above was used. Fabs

were generated as described above and incubated with the EBOV GP∆TM trimer at a ratio of 1:10 for overnight at 4°C. Complexes were then deposited onto a carbon coated copper mesh grid and stained with 1% uranyl formate. Samples were imaged on a Tecnai F12 microscope using the automated image acquisition software Leginon(35). Images were collected at 52,000 x magnification resulting in a final pixel size at the specimen level of 2.05A using a Tietz 4K CMOS detector. Images were automatically uploaded to and processed within our Appion database(36). Individual complexes were extracted from raw images using DogPicker(37) binned by 2 and placed into a stack. The stack was then subjected to reference free 2 dimensional classification using MRA/MSA [PMID 14572474]. Class averages that did not respond to Fab-EBOV∆TM complexes were removed from all subsequent analyses. A subset of 2D class averages was used to create an initial model using common lines within EMAN2(38). The raw particle stack was then refined against the initial model using EMAN2 to yield the final 3D volumes.

UCSF Chimera was used for modeling and figure generation(39).

EBOV challenge studies in mice The lethal mouse-adapted EBOV mouse model was developed at the U.S. Army

Medical Research Institute of Infectious Diseases (USAMRIID) by serial passages of EBOV (Zaire) in progressively older suckling mice(23). Female BALB/c mice, aged 6 to 8 weeks, were purchased from Charles River Laboratory. Upon arrival, mice were housed in microisolator cages in an animal biosafety level 4 containment area and provided chow

and water ad libitum. On day 0, mice were infected intraperitoneally (i.p.) with 100 p.f.u. of mouse-adapted EBOV. Two days post-infection, groups of mice (10 mice per group) were treated i.p. with a single dose (100 µg) of antibody. Negative control mice received PBS. Mice were monitored daily (twice daily if there were clinical signs of disease) for 28 days post-infection. Group weights were taken on days 0-14, and on days 21 and 28 post-infection. Survival was compared using the log-rank test in GraphPad PRISM 5. Differences in survival were considered significant when the P value was less than 0.05. Research was conducted under an IACUC approved protocol in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations relating to animals and experiments involving animals. The facility where this research was conducted is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011.

Fig. S1. Plasma binding and neutralization. (A) ELISA binding of donor plasma to EBOV GP∆TM. (B) Plasma neutralization of EBOV. PRNT50 is achieved at a plasma dilution of 1:320. Serial dilutions of plasma were tested for neutralizing activity in a live virus plaque reduction assay. Negative control plasma from an EBOV naïve subject was tested at a 1:40 dilution. The data shown are representative of two independent experiments.

101 102 103 104 1050

1

2

3

4

5

Reciprocal plasma dilution

OD

450n

mEBOV Subject 45Healthy donor

Supplemental figure 1

A

B

Negative control plasma (1:40 dilution)

0

20

40

60

80

100

120

Res

idua

linf

ectiv

ity(%

)

101 102 103 1040

20

40

60

80

100

Reciprocal plasma dilution

Res

idua

linf

ectiv

ity(%

)

Fig. S2. B cell sorting. FACS plots show EBOV GP∆TM reactivity of IgG+ B cells from Subject 45 and a healthy donor control. EBOV GP-reactive B cells from Subject 45 were sorted into 96-well plates and variable genes were amplified by RT-PCR.


Healthy donor

Subject 45

IgG

IgG

IgG

IgG

CD20

CD20 EBOV GP

EBOV GP

Fig. S3. Anti-GP antibody repertoire. (A) Clonal lineage analysis. Each slice represents one clonal lineage; the size of the slice is proportional to the number of clones in the lineage. The total number of clones is shown in the center of the pie. Clonal lineages were assigned based on the following criteria: 1) matching of variable and joining gene segments; 2) identical CDR3 loop lengths; and 3) >80% homology in CDR3 nucleotide sequences. (B) Igκ and Igλ expression among all GP-binding mAbs. (C) CDRH3 length distribution. (D) VH repertoire analysis. (E) Vκ repertoire analysis. (F) Somatic hypermutation. Red bars indicate the mean number of nucleotide substitutions. Each clonal lineage is only represented once in B-E. Data for non-GP reactive IgGs were derived from published sequences obtained by high-throughput sequencing re-arranged antibody variable gene repertoires from healthy individuals(15, 16).

349

VH VL0

5

10

15

20

#of

nucl

eotid

esu

bstit

utio

ns


BA

C D

Vk Vl0

20

40

60

80

100

%R

eper

toir

e

GP reactive IgGsNon-GP reactive IgGs

6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 3002468

10121416

CDRH3 Length

%R

eper

toir

e


E F

VH1-18VH1-2

VH1-24VH1-3

VH1-46

VH1-69VH1-8

VH2-26VH2-5

VH2-70

VH3-11

VH3-15

VH3-21

VH3-23

VH3-30

VH3-33

VH3-48

VH3-49

VH3-53

VH3-64

VH3-66VH3-7

VH3-73

VH3-74

VH4-30_

2

VH4-304

VH4-31

VH4-34

VH4-39VH4-4

VH4-59

VH4-61

VH5-51VH5-a

0

5

10

15

%R

eper

toir

e


VK1-12

VK1-13

VK1-16

VK1-17

VK1-27

VK1-33

VK1-39VK1-5

VK1-6VK1-9

VK1D-17

VK2-28

VK2-30

VK2-40

VK3-11

VK3-15

VK3-20VK4-1

0

10

20

30

40

%R

eper

toir

e


Fig. S4. Antigen binding properties of anti-GP mAbs. (A) Binding responses of anti-GP IgGs for Zaire GP∆TM and Zaire GP∆muc. (B) Association rate constants of anti-GP IgGs for Zaire GP∆TM and Zaire GP∆muc. Binding responses and association rate constants were determined by BLI measurements. The data shown are representative of two independent experiments.

0.01 0.1 1 100.01

0.1

1

10

Zaire GPDmuc response units

Zaire

GP D

TMre

spon

seun

its


A B

103 104 105 106103

104

105

106

Zaire GPDmuc Kon (1/Ms)

Zaire

GP D

TMK

on(1

/Ms)

Fig. S5. Epitopes shared between EBOV GP and EBOV sGP. (A) Top, the sGP transcript is displayed showing the location of the transcriptional editing site within the GP gene that leads to the production of the full-length EBOV GP transcript. Below, a schematic of the full-length EBOV GP transcript showing the regions that EBOV GP and sGP have in common. (B) The predicted monomeric sGP protomer is modeled based on the residues shared between the EBOV GP crystal structure (PDB ID: 3CSY) and sGP (left)(6). The structure of the sGP-specific region (red) is unknown and is shown as a dashed line. In order to display potential solvent exposed epitopes shared between EBOV GP and sGP, residues shared between EBOV GP and sGP are shown as cartoon and remaining residues are displayed with a surface (right).

B

A

Glycan Cap

HR2

GP2

GP1

MucinDomain

Fusion Loop

GP1

N

C

EBOV sGP(monomer)

EBOV GP

Regions containing shared epitopes between sGP and GP

Furin CleavageSite

SPGP1Core

34-215

GP1Glycan Cap

216-313

GP1Mucin Domain

314-501

GP2Fusion515-550

GP2HR2

613-637

GP2638-676

GP2502-514

GP2551-612

GP Transcript

sGP-specific Region

GP2Fusion515-550

TranscriptionalEditing Site

sGP-specific Region296-364

GP1Glycan Cap

216-295

GP1Core

34-215SP

sGP Transcript

SignalPeptide

1-33

GP1Mucin Domain

314-501

GP2HR2

613-637

GP2638-676

GP2502-514

GP2551-612

Fig. S6. Antibody competition assays. (A) Competition of sGP reactive mAbs with 1H3 and 13C6. (B) Competition of non-sGP reactive mAbs with KZ52 and mAbs targeting undefined GP-specific epitopes (ADI-15972, ADI-15983, ADI-15810, ADI-15933). Results are expressed as the fold reduction in antigen binding in the presence of saturating concentrations of competitor Fab relative to an antigen-only control. IgGs with greater than three-fold reduced binding in the presence of control Fab are considered competitors. The data shown are representative of two or more independent experiments.

1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93 95 97 9910110

310

510

710

911

111

311

511

711

90

10

20

30

40

50

60

70

80

90

100

GP-specific binders

Clone index

Fold

redu

ctio

nin

antig

en-b

indi

ng

1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101

105

109

113

117

121

125

129

133

137

141

145

149

153

157

161

165

169

173

177

181

185

189

193

197

0

10

20

30

sGP cross-reactive binders

Clone index

Fold

redu

ctio

nin

antig

en-b

indi

ng


KZ5213C6ADI-15974ADI-15983ADI-15810ADI-15933

A

B

1H313C6

Fig. S7. GP binding cross-reactivity analysis. ELISA binding of selected KZ52 competitors (A) or KZ52 non-competitors (B) to Zaire GP∆TM, Sudan GP∆TM, and Bundibugyo GP∆TM. ELISA binding is expressed as the OD405 reading at a concentration of 0.2 µg/ml. The data shown are representative of two independent experiments.

ADI-157

34

ADI-157

41

ADI-157

43

ADI-157

59

ADI-157

62

ADI-157

72

ADI-157

80

ADI-157

83

ADI-157

84

ADI-157

86

ADI-158

22

ADI-158

39

ADI-158

42

ADI-158

43

ADI-158

54

ADI-158

60

ADI-158

61

ADI-158

65

ADI-158

71

ADI-158

77

ADI-158

87

ADI-159

08

ADI-159

09

ADI-159

12

ADI-159

35

ADI-159

46

ADI-159

53

ADI-159

77

ADI-159

78

ADI-159

95

ADI-160

05

ADI-160

31

ADI-160

390

1

2

3O

D40

5

ADI-157

32

ADI-157

48

ADI-157

53

ADI-157

57

ADI-157

77

ADI-157

79

ADI-157

82

ADI-158

08

ADI-158

10

ADI-158

12

ADI-158

16

ADI-158

19

ADI-158

20

ADI-158

41

ADI-158

48

ADI-158

82

ADI-158

84

ADI-159

01

ADI-159

16

ADI-159

25

ADI-159

33

ADI-159

41

ADI-159

51

ADI-159

54

ADI-159

56

ADI-159

63

ADI-159

66

ADI-159

69

ADI-159

71

ADI-159

74

ADI-159

76

ADI-159

83

ADI-159

84

ADI-159

96

ADI-159

98

ADI-160

50

ADI-160

53

ADI-160

610

1

2

3

OD

405

Zaire GPDTMBundibugyo GPDTMSudan GPDTM

BA


Fig. S8. Neutralizing activity of control IgGs. (A) Yeast- and CHO-produced KZ52 IgG show similar levels of neutralizing activity. (B) Yeast-produced anti-hen egg lysozyme (HEL) IgG and a CHO-produced anti-Venezuelan equine encephalitis virus (VEEV) IgG fail to neutralize at a concentration of 100 µg/ml. The data shown are representative of two or more independent experiments.

Sample Concentration (ug/ml) Plaque count

Yeast produced anti-HEL IgG 100 >200

Negative control VEEV IgG 100 >200

Virus only - 340

A

B


0 1 2 3 4 5 60

20

40

60

80

100

IgG concentration (ug/ml)

Res

idua

linf

ectiv

ity(%

)

CHO-produced KZ52Yeast-produced KZ52

Fig. S9. Mean and range of IgG concentrations tested in initial neutralization screening. Horizontal bars represent the mean IgG concentrations tested. The number of mAbs tested from each competition group are shown at the top of the corresponding bar.

13C6 an

d/or 1H3 co

mpetitors

ADI-158

10co

mpetitors

ADI-159

74co

mpetitors

ADI-159

33co

mpetitors

KZ52co

mpetitors

Mucin-lik

e domain

ADI-159

83co

mpetitors

Undefined

0

20

40

60

80

100

120

140

IgG

conc

entr

atio

n( m

g/m

l) n=56n=180 n=29 n=3

n=2

n=24

n=2

n=17


Fig. S10. Negative stain EM reference free 2D class averages of Fab/EBOV GPΔTM complexes. The top row of particles for each set of images is false colored to show the GP in cyan and the Fab in yellow. ADI-15731, ADI-15762, ADI-15734, and ADI-15758 resulted in 3D reconstructions. The particles for ADI-15859 did not result in a reconstruction due to preferred orientations on the EM grid and sub-stoichiometric binding.

Fig. S11. Raw EM data and resolution estimation. Representative raw micrographs of particles (left) used for EM reconstructions with corresponding FSC curves (right) used to determine the resolution at an FSC cutoff of 0.5. The number of particles for each reconstruction and the estimated resolution is indicated.

Fig. S12. Comparison of negative stain EM reconstructions to known mAb epitopes. (A) Fabs 1H3 and 13C6(4) are superimposed on the structure of ADI-15731. (B) Fabs 13C6 and KZ52(4) are superimposed on the structure of ADI-15762. (C) Fab KZ52 is superimposed on the structure of ADI-15734. (D) Fab KZ52 is superimposed on the structure of ADI-15758. The dashed lines represent the viral stalk. Side views (top) and top views (bottom), relative to the viral membrane, are shown. TM = transmembrane, CT = cytoplasmic tail.

Fig. S13. Body weight loss (group averages) of mice (n = 10 per group) that were infected with 100 p.f.u. of MA-EBOV and treated intraperitoneally with a single dose of the indicated mAbs at two dpi (represented by a dotted black line on the graph). Negative control mice were treated with PBS. MAb 2G4 is included for comparison.

5 10 15 20 25 30

-20

-10

0

10

20

30

Days post-infection

Bod

yw

eigh

tlos

s(%

)PBS2G4 controlADI-15956ADI-16061ADI-15974ADI-15758ADI-15999ADI-15820ADI-15848

5 10 15 20 25 30

-20

-10

0

10

20

30

Days post-infection

Bod

yw

eigh

tlos

s(%

) PBS2G4 controlADI-15818ADI-15878ADI-15734ADI-15784ADI-15772ADI-15742

5 10 15 20 25 30

-20

-10

0

10

20

30

Days post-infection

Bod

yw

eigh

tlos

s(%

) PBS2G4 controlADI-15731ADI-15932ADI-15940ADI-15744ADI-16037ADI-16044ADI-15817

5 10 15 20 25 30

-20

-10

0

10

20

30

Days post-infection

Bod

yw

eigh

tlos

s(%

) PBS2G4 controlADI-15960ADI-15903ADI-15959ADI-15765

ADI-15974 competitors KZ52 competitors

13C6 competitors Undefined epitopes

Fig. S14. Summary of the antigenic sites targeted by the anti-GP antibody repertoire. Results are derived from both competitive binding data and cryo-EM data.

Glycan capUndefined, sGP reactiveGP1/GP2 interfaceHR2

ADI-15933 competitors321 52%17%

1%

10%

1%

Undefined, sGP non-reactiveMucin-like domain

17%

1% 1%

ADI-15983 competitors


Table S1. Efficiency of anti-GP mAb isolation from peripheral B cells. TotalnumberofIgG+Bcellssorted 600Numberofantibodiescloned 420(70%)NumberofclonesexpressingIgG 378(63%)NumberofEBOVGPbinders 349(58%)

Table S2. Antibody sequencing.Lineage# Clonename VHGermline CDRH3 CDRH3Length VLGermline VLCDR3 CDRL3Length

#ofVHnucletotidesubstitutions

#ofVLnucletotidesubstitutions

#ofcloneswith100%IgHandIgLchaingenesequencehomology

1 ADI-15878 VH3-23 AKDHRVWAAGYHFDY 15 VK1-5 QQYYSSPT 8 5 2 1

1 ADI-15742 VH3-23 AKDHRVWAPGYYFDH 15 VK1-5 QQYNRSPT 8 6 1 1

2 ADI-15925 VH3-30 AKGAVVIAMLNYFDS 15 VK4-1 QQYYSTPQT 9 0 3 1

2 ADI-15916 VH3-30 AKGAVVIAMLNYFDY 15 VK4-1 QQYYSTPQT 9 4 5 1

2 ADI-15841 VH3-30 AKGAVVIAMLNYFDY 15 VK4-1 QQYYNTPQT 9 4 15 1

3 ADI-15823 VH3-23 AKNIGVLAVIYSAEDDAFDM 20 VK1-39 QQSYRTPYG 9 12 3 1

3 ADI-19656 VH3-23 AKNIGVLAVIYSAEDDAFDM 20 VK1-39 QQSYRTPYG 9 12 4 1

4 ADI-15977 VH4-34 ARALPRGGNYRTFDY 15 VK2-28 MQGLQTPLT 9 3 1 1

4 ADI-16031 VH4-34 ARALPRGGNYRTFDY 15 VK2-28 MQGLQTPLT 9 3 1 4

4 ADI-15839 VH4-34 ARALPRGGNYRTFEY 15 VK2-28 MQGLQTPLT 9 4 0 1

5 ADI-15843 VH4-34 ARAWLRSRGYPSFDY 15 VK2-28 MQALQTLT 8 1 0 1

5 ADI-15912 VH4-34 ARAWLRSRGYPSFDY 15 VK2-28 MQALQTLT 8 3 0 1

5 ADI-19657 VH4-34 ARAWLRSRRYPSFDY 15 VK2-28 MQALQTLT 8 2 0 1

5 ADI-15861 VH4-34 ARAWLRSSSYPSFDY 15 VK2-28 MQALQTLT 8 3 0 1

5 ADI-15978 VH4-34 ARAWLRTSWYPSFDY 15 VK2-28 MQALQTLT 8 1 0 1

6 ADI-15784 VH1-18 ARDLTPRDGMDV 12 VK2-28 MQALQTPRT 9 7 3 1

6 ADI-15935 VH1-18 ARDLTPRYGLDV 12 VK2-28 MQALQSPWT 9 10 4 1

6 ADI-15780 VH1-18 ARDLTPRYGMDV 12 VK2-28 MQALQTPRT 9 3 1 1

6 ADI-15772 VH1-18 ARDLTPRYGMDV 12 VK2-28 MQALQTPRT 9 6 4 1

7 ADI-15974 VH1-46 ARDRYPTVTKYFGMDV 16 VK3-11 QQRSNWPPSIT 11 8 3 1

7 ADI-15956 VH1-46 ARDRYPTVVKYFGMDV 16 VK3-11 QQRSNWPPSIT 11 1 3 1

7 ADI-15758 VH1-46 ARDRYPTVVNYFGMDV 16 VK3-11 QQRSNWPPSIT 11 3 4 1

8 ADI-15880 VH3-7 AREAFLEWLAPLGHYYMDV 19 VK3-20 QLYGSSFRT 9 3 1 1

8 ADI-15964 VH3-7 AREAFLEWLAPLGHYYMDV 19 VK3-20 QLYGRSFRT 9 4 2 1

8 ADI-15910 VH3-7 AREAFLEWLAPLGYYYMDV 19 VK3-20 QQNGRSPRT 9 2 0 1

9 ADI-15969 VH3-7 AREEDVNIAMGALGY 15 VL3-1 QAWDSSTAV 9 1 1 1

9 ADI-15984 VH3-7 AREEDVNIAMGALGY 15 VL3-1 QAWDSGTAV 9 6 1 1

10 ADI-15825 VH3-21 AREGITIFGVLIHPVMDV 18 VK3-20 HQYGNSPRT 9 5 1 1

10 ADI-15863 VH3-21 AREGITILGVLIHPVMDV 18 VK3-20 HQYGSSPRT 9 10 1 1

11 ADI-15895 VH3-48 AREGPSPSDSYYYYMDV 17 VL3-19 HSRDSSGNPWV 11 4 5 1

11 ADI-15858 VH3-48 AREGPTPMDYYYYYMDV 17 VL3-19 NSRDSSGNPWV 11 2 8 1

11 ADI-16053 VH3-48 AREGPTPMDYYYYYMDV 17 VL3-19 QSRDISGNPWV 11 5 8 1

12 ADI-15791 VH3-21 ARGDDFLVVAGTIDYSHYVMDV 22 VK1-5 QQYNSYPRT 9 4 5 1

12 ADI-16042 VH3-21 ARGDDFVVVAGTIDYSHYVMDV 22 VK1-5 QQYNSYPRT 9 4 5 1

13 ADI-15881 VH4-31 ARGHSGDYSPPFFDY 15 VK3-20 QQYRSSPT 8 3 1 1

13 ADI-15857 VH4-31 ARGHSGDYSPPFFDY 15 VK3-20 QQYRSSPT 8 4 4 1

14 ADI-16028 VH4-30-4 ARGPKSLAGIAMTGAFDY 18 VK1-5 QQYNTYSFT 9 3 3 1

14 ADI-16038 VH4-30-4 ARGPKSLSGIAMAGAFDY 18 VK1-5 QQFNSYPFT 9 3 2 1

15 ADI-15820 VH4-59 ARHTPIRYSSGWYLDY 16 VK3-11 QQRSNWPPAIT 11 5 2 1

15 ADI-15901 VH4-59 ARHTPIRYSSGWYLDY 16 VK3-11 QQRSKWPPAIT 11 3 5 1

16 ADI-15762 VH3-48 ARTLGYCSGGSCYSVSHDAFDI 22 VK1-5 QQCNSYPWT 9 6 3 1

16 ADI-15818 VH3-48 ARTLGYCSGGSCYSVSHDAFDI 22 VK1-5 QQYDSYPWT 9 4 4 1

17 ADI-15941 VH1-2 ARVNHYDSSGYYGWFDP 17 VK4-1 QQYYTTPYT 9 0 0 1

17 ADI-15845 VH1-2 ARVNYYDSSGYYGWFDP 17 VK4-1 QQYYSTPYT 9 0 1 1

18 ADI-15954 VH1-46 RRSGWSVTDYFDY 13 VK2-40 MQRIELPHT 9 7 1 1

18 ADI-15777 VH1-46 RRSGWSVTDYFDY 13 VK2-40 MQRLEFPHT 9 3 2 1

18 ADI-15996 VH1-46 RRSGWSVTDYFDY 13 VK2-40 MQRIEFPHT 9 5 3 1

19 ADI-15951 VH1-2 VVRYFDWNGPFDY 13 VK1-27 QKYNSVPWT 9 9 2 1

19 ADI-15966 VH1-2 VVRYFDWNGPIDY 13 VK1-27 QKYDSAPWT 9 8 0 1

20 ADI-15732 VH3-30 AKGGVLIAIINYFDY 15 VK1-5 QQYNSFYT 8 0 6 3

20 ADI-15819 VH3-30 AKGGVLIAIINYFDY 15 VK1-5 QQYNSFYT 8 6 6 1

21 ADI-16061 VH1-46 ARDRYPVLFATDYGMDV 17 VK3-11 QQRSIWPPGVT 11 8 1 1

21 ADI-15848 VH1-46 ARDRYPVLVATDYGMDV 17 VK3-11 QQRSIWPPGVT 11 2 4 1

22 ADI-16010 VH3-23 AAERLQWFDYLSSTDYYMDV 20 VK3-11 QQRSNWRLT 9 7 3 1

23 ADI-15735 VH3-15 AAGPIKEYHDFLTGYYEVDY 20 VK1-39 QQTYSPPLT 9 4 10 1

24 ADI-15800 VH3-21 AGAEYSYGFGVDAFDI 16 VK3-15 QQYNNWPPIT 10 2 1 2

25 ADI-16060 VH4-59 AGDQGFCTNGVCFRVGWFDP 20 VK1-5 QQYKIYPMYT 10 3 2 1

26 ADI-15809 VH2-5 AHIGGKDYYHSFGSYYQTHAFDI 23 VK1-13 QQFKSYPLT 9 4 1 1

27 ADI-16006 VH2-5 AHSLVAYSNSPVAFGSSWFLSSETTNYFDP 30 VK3-11 QQRSNWPLT 9 1 2 1

28 ADI-15968 VH2-5 AHSQTPVSRFLDWSQRLYFDY 21 VL1-44 AAWHDSLNGPV 11 1 2 1

29 ADI-16047 VH2-5 AHVNVITVFGVIIVPSGWFDP 21 VK3-20 QQYATSPASSPA 12 8 8 1

30 ADI-15804 VH1-46 AIFVLSIGGYQSY 13 VK2-40 MQRLEFPWT 9 6 0 1

31 ADI-16023 VH5-51 AIRWFGGDPFDY 12 VK3-20 QQYGSSLWT 9 16 3 1

32 ADI-15883 VH3-30 AKAGDYIWGSYRYFAGMLKPFDT 23 VK3-15 QHYNNWPQT 9 1 1 1

33 ADI-15889 VH1-2 AKAWPTDIVILPDALSGFDA 20 VK3-20 QQYGSSPYT 9 7 2 2

34 ADI-15837 VH3-23 AKDALTVTTVLWGSDQYYFDY 21 VK1-39 QQSYRLWT 8 5 2 1

35 ADI-16014 VH3-23 AKDHYDFWSAYQLDV 15 VL1-51 GTWDSSLSSGGV 12 3 0 1

36 ADI-15828 VH3-23 AKDLRSWDIVVVPAVHGAFDI 21 VK1-5 QQYNSYSQT 9 3 1 1

37 ADI-15970 VH3-23 AKDQDFWSGYSPPIT 15 VL1-51 GTWDFSLSAVV 11 3 0 1

38 ADI-15986 VH3-23 AKDRDFWSGSRDFDY 15 VL1-51 GTWDSSLSGGLYV 13 8 1 1

39 ADI-16004 VH3-21 AKDRGRRGVNWFDP 14 VK1-5 QQYNSYSRT 9 6 1 1

40 ADI-16036 VH3-23 AKDSEVFGVLILPRGMDV 18 VK3-15 QQYNNWLYT 9 0 1 1

41 ADI-16011 VH3-30 AKDSPGEQWLILSYYGMDV 19 VK2-28 MQALQTPLA 9 6 1 1

42 ADI-15896 VH3-33 AKEGFLEWLSPSDYYFGMDV 20 VK2-28 MQALQTGT 8 6 0 1

43 ADI-15774 VH3-23 AKEHYYNILTGYLRAHNWFDP 21 VK1-39 QQTYSTPPFT 10 5 6 1

44 ADI-16059 VH3-23 AKEKDFWNGYYIDY 14 VL1-51 GTWDISLNAWV 11 6 3 1

45 ADI-15767 VH3-23 AKESEWLFLSALDY 14 VK3-15 QQYDNWPRT 9 5 5 1

46 ADI-15924 VH3-30 AKESFSGRQLLVPWSFDF 18 VK1-9 QQLDSYPQIT 10 9 3 1

47 ADI-15836 VH3-23 AKGANFWGAWSDYYPV 16 VL1-51 GTWDSSLSAGV 11 3 2 1

48 ADI-15811 VH3-30 AKGRAPVAGTSYFDY 15 VK1-27 QKYNSAPPT 9 0 0 1

49 ADI-15999 VH3-23 AKGRTSSA 8 VK3-20 HQYGTSPWT 9 6 5 1

50 ADI-15850 VH3-23 AKGSVVVVASTLYYFDY 17 VK1-5 QQYDRYPWT 9 2 10 1

51 ADI-15785 VH3-30 AKGTVIIAMLNYFDY 15 VK4-1 QQYYSTPQT 9 5 4 1

52 ADI-15751 VH3-23 AKGYDFWSAYPDY 13 VL1-47 AAWDDSLSGVV 11 5 2 1

53 ADI-16013 VH3-48 AKLGAPEQWLVSSKESYFDY 20 VK1-39 QQSYNTPWT 9 3 3 1

54 ADI-15827 VH3-23 AKPKEGSEWLILRFDAFDV 19 VK3-20 LQYGTSPPVYT 11 7 3 1

55 ADI-15847 VH3-23 AKSGTVNYYFYYMDV 15 VK1-5 QHYNSYSLFT 10 3 3 1

56 ADI-15781 VH5-10-1 AKTFYDTDY 9 VK1D-17 LQHNSYPWT 9 4 2 1

57 ADI-15939 VH3-23 AKVEGEWSDIVVVVAATPFDY 21 VL3-21 QVWHSSSDHVI 11 7 6 1

58 ADI-15768 VH3-23 AKVGMTAVTKGMEIDYSYGMDV 22 VK3-20 QQYGSSMA 8 6 3 1

59 ADI-15927 VH1-46 ALLAGYSGFYYLVPFDY 17 VK1-39 RQSYSTPYT 9 5 2 1

60 ADI-15778 VH3-48 ARAAADYNYGMDV 13 VL1-40 QSYDDTLSGWV 11 10 7 1

61 ADI-15877 VH4-59 ARAAKGCTSTSCYEWDV 17 VK2-28 MQALQTPLT 9 2 1 1

62 ADI-16025 VH4-39 ARADMLHEFIINRVAFDY 18 VL2-14 SSYTSISTWV 10 4 3 1

63 ADI-15856 VH4-39 ARADMLQGIIITRVAFDY 18 VL2-14 SSYTSSNTWV 10 6 7 6

64 ADI-15868 VH3-33 ARADSTDDYYYYYMDV 16 VK1-39 QQSSRTPYT 9 0 3 1

65 ADI-15739 VH1-2 ARAEVLGLVEQLMEFNWFDP 20 VK1-39 QQSYNTLS 8 3 3 1

66 ADI-15769 VH3-21 ARAGGSGTSDGMDYYYYSGMDV 22 VK1-5 QQYNSYRYT 9 4 1 1

67 ADI-16062 VH4-34 ARALRTIWDGYYNYMDV 17 VK1-39 QQSYSTPRRVT 11 0 0 1

68 ADI-15733 VH3-21 ARALSMGELFVAGTIDY 17 VK1-39 QQSYTTLLS 9 5 3 1

69 ADI-15744 VH1-3 ARAPDDSIGMLTAYGPLDH 19 VL3-21 QVWDSRSDHWV 11 11 6 1

70 ADI-15763 VH1-18 ARARQLLRDLLFAPQGMDV 19 VK1-6 LQDYNYPWT 9 8 1 1

71 ADI-15988 VH4-59 ARASITGFGVLIMEGVFDS 19 VK3-20 QQYGSSPS 8 8 3 1

72 ADI-16029 VH3-13 ARAVFGSSAFDI 12 VK3-20 QQYGSSPLT 9 3 1 1

73 ADI-15902 VH3-21 ARAVGELLFYTDAFDI 16 VK3-15 QQHNRPPFT 9 6 7 1

74 ADI-16030 VH1-2 ARAWPTDIVILPTALTGLDP 20 VK3-20 QQYGSSPYT 9 7 3 1

75 ADI-16007 VH1-18 ARCSELYYDILTSSYFFDY 19 VK1-5 QQYKTYSPALT 11 4 4 3

76 ADI-15835 VH1-3 ARDAGPDQLLWLSDYHYMDV 20 VK2-28 MQALQIPPT 9 2 5 1

77 ADI-15929 VH3-21 ARDAPITSSWGTGYYDYYYMDV 22 VK1-5 QQYNSYRT 8 8 3 1

78 ADI-15840 VH3-11 ARDARISYDILTGYSYYYYMDV 22 VK1-5 QQYNSYRT 8 5 1 1

79 ADI-15876 VH3-7 ARDASDFWSPNFDY 14 VK1-6 LQDYNYPWT 9 1 3 1

80 ADI-16019 VH4-59 ARDDYFGGVKI 11 VL6-57 QSYDSSIWV 9 5 3 1

81 ADI-15838 VH3-21 ARDEFGGIVVIPAAAGY 17 VK1-39 QRSHSTPYT 9 5 2 1

Table S2 (continued). Antibody sequencing.Lineage# Clonename VHGermline CDRH3 CDRH3Length VLGermline VLCDR3 CDRL3Length




82 ADI-15904 VH3-30 ARDFWLLLDAFDI 13 VK3-15 QQYNNWPRT 9 11 0 1

83 ADI-15955 VH3-21 ARDGALPADFVLLPAVNCFDP 21 VK1-12 QQSNSLPPT 9 7 1 1

84 ADI-15756 VH1-18 ARDGFSDIGMVEFYYYGMDV 20 VK1-17 LQRNSYPYT 9 7 2 1

85 ADI-16003 VH4-4 ARDGGGSNSSGFRVFRATFDY 21 VL2-23 CSYTNRGAV 9 0 2 1

86 ADI-15826 VH1-18 ARDGQTFYDILTTQWYGMDV 20 VK1-39 HQSYSTPRRDT 11 3 2 1

87 ADI-15808 VH3-33 ARDGTYYYGSGSEHWDYYGLAV 22 VK2-28 MQALQTRT 8 2 2 1

88 ADI-15993 VH3-21 ARDHKEYISDWGVGYYYSGMDV 22 VK3-20 QQYGSSPPT 9 2 0 1

89 ADI-15915 VH3-21 ARDIYDSGGYYYGGGTDAFDI 21 VL3-19 NSRDSSGNRV 10 2 0 1

90 ADI-15981 VH1-69 ARDLEWLGYCTGGVCYASSMDV 22 VK3-15 QQYNNWPIT 9 4 1 2

91 ADI-16037 VH3-21 ARDLGDILIVPAAFDY 16 VL1-44 ATWDDSLNGPV 11 5 2 1

92 ADI-15854 VH3-21 ARDLGHGVSYGYGTYYDY 18 VK4-1 QQYYSTLYT 9 1 0 1

93 ADI-15759 VH1-46 ARDLMGWQHNLGGFDY 16 VK1-5 QQSGYT 6 1 2 1

94 ADI-15846 VH4-4 ARDLRAPTFSWTSRLTPKEKNSDN 24 VK2-28 MQALQTPLT 9 7 2 1

95 ADI-15831 VH3-21 ARDLRYFDWLYHDAFDI 17 VK3-20 QQYAGSPLT 9 5 3 1

96 ADI-16009 VH3-21 ARDLSFGGIIFINAFDL 17 VK1-39 QQGSSTPFT 9 4 4 1

97 ADI-15921 VH1-46 ARDNPGDQWLVPYNSYYYMDV 21 VK3-11 QQRSNWPRGIT 11 4 1 1

98 ADI-15794 VH1-69 ARDNSGYDLNPLHY 14 VK3-20 QQYGSNPT 8 4 0 1

99 ADI-15741 VH4-4 ARDPGRGRDYYEMDV 15 VK2-28 MQALQTPA 8 4 0 1

100 ADI-15860 VH4-59 ARDPRYYDYFRGSYGHYGLDV 21 VL3-1 QTGGEV 6 3 2 1

101 ADI-15842 VH1-46 ARDRAQAGTNNWFDP 15 VK1-12 QQANSFPLT 9 11 1 1

102 ADI-15975 VH4-4 ARDRAVSINYYYYMDV 16 VK3-11 QQRSNWPKMYT 11 5 1 1

103 ADI-15792 VH4-61 ARDREVVPGLSGLLYSFHGMDV 22 VK1-39 QQSHSTPRT 9 6 3 1

104 ADI-15864 VH1-18 ARDRGTFTYVSGLVVAAYLDAFDI 24 VK3-20 QQYDSSPRT 9 5 7 1

105 ADI-15834 VH1-18 ARDRLLFYHILTASYPFDY 19 VK3-20 QQYGSSLSIT 10 14 3 1

106 ADI-15803 VH3-53 ARDRLLWFTELLYRDNGMDV 20 VK1-39 QQSYRSPRT 9 4 5 1

107 ADI-15897 VH3-48 ARDRMPKYDILTGPESAGMDV 21 VK1-39 QQSYSNSRT 9 4 3 1

108 ADI-15867 VH4-30-4 ARDRYNTDYGNVLYYFYGMDV 21 VK1-5 QQYHSYSPCT 10 4 4 1

109 ADI-15945 VH3-11 ARDSMVQGVFIHGPNDY 17 VL3-21 QVCGTGCDSWV 11 3 8 1

110 ADI-15817 VH1-18 ARDSTLLAYSGYDNTIFLHNGMAV 24 VK3-20 QQYGSSPQT 9 1 3 1

111 ADI-15870 VH1-18 ARDTAFMFASFGVGYHYNGMDV 22 VK3-20 QQYGRSPWT 9 5 4 1

112 ADI-15761 VH1-18 ARDVEIAVVAVATLSRNFGMDV 22 VK1-5 QQYKSYSWT 9 6 2 1

113 ADI-15937 VH1-18 ARDVLRFLEWLLHLRTNDYNGMDV 24 VK2-30 MQGTHWPWT 9 10 1 1

114 ADI-16056 VH3-21 ARDVTDSSGYLYLNAFDL 18 VK3-15 QQYNKWPPWT 10 3 0 1

115 ADI-15821 VH3-21 AREAWDLDIVATILLDY 17 VK1-17 LQYNSYPYT 9 6 2 1

116 ADI-15980 VH1-2 AREEGRNSLRYYYGMDV 17 VK2-28 MQALQTPYT 9 0 0 1

117 ADI-15959 VH3-21 AREEITISGVLVHPVMDV 18 VK3-20 HQYGSSPRT 9 15 0 1

118 ADI-15922 VH1-69 AREETIGGIVVSQFFDP 17 VL1-44 AAWDDSLNAYV 11 10 3 1

119 ADI-15738 VH3-30 AREGAVRLDYNILTGYYLSSFDI 23 VK3-15 QQYNTWPPEYT 11 7 0 2

120 ADI-15948 VH3-30 AREGFCSEGICTLGYQLDY 19 VL1-40 QSYDSSLRLWV 11 9 3 1

121 ADI-15737 VH3-21 AREGITLGGVLVINALDI 18 VK3-15 QQYKKWPYT 9 12 6 1

122 ADI-15899 VH3-30 AREKRFLEWLSVGDAFDI 18 VK3-15 QQYNNWPRT 9 4 0 1

123 ADI-16035 VH1-2 ARELSGDCSGGVCSGSGYFDY 21 VK4-1 QQYYSPLT 8 1 1 1

124 ADI-15799 VH3-74 ARELTVNYPGSGSSFMVGTYYHYALDV 27 VK3-20 QQYGTSPRIT 10 9 2 1

125 ADI-15907 VH3-30 ARENYGDDTLILVGSYYGMDV 21 VK1-17 LQHNSYPPT 9 8 0 1

126 ADI-15832 VH3-33 AREPGFCSGGTCFQADYFDY 20 VK3-11 QQRSNAYT 8 6 2 1

127 ADI-15928 VH4-4 ARERLLWLKNLLYNENGLDV 20 VK1-33 QQYASLPYT 9 10 2 1

128 ADI-15766 VH1-69 ARESEGSGWNPFDY 14 VK3-20 QHYGSSPI 8 9 1 1

129 ADI-15971 VH3-33 ARESIRVGDTRSYFDY 16 VK3-11 QQRFHWPLT 9 20 7 1

130 ADI-15995 VH1-46 ARETSKHDFWSGSPYHYYYMDV 22 VL2-11 CSYADSHTDV 10 2 2 1

131 ADI-15764 VH1-3 ARETSKYDILTGPHDYYMDV 20 VK1-39 QQSYSAPMYT 10 6 2 1

132 ADI-15886 VH3-53 ARETVFGSQYYGMDV 15 VK2-28 MQALQTPYT 9 2 1 1

133 ADI-16008 VH1-69 AREVGDMIGVILYTYYYMDV 20 VK3-20 QQYGSSPPVT 10 6 1 1

134 ADI-15909 VH6-1 AREWELRYDAFDI 13 VL3-25 QSADSSGTYRV 11 1 0 1

135 ADI-15967 VH3-48 AREYFRSPGSLLRFSGNWFDP 21 VL3-21 QVWDSSSDAYV 11 4 5 1

136 ADI-15782 VH4-4 ARFTDWYYDILTGKKEDFYYIDV 23 VK1-39 QQSYTTPRT 9 3 3 1

137 ADI-15938 VH4-34 ARGAGIIFGGVVLTNNNWGDV 21 VK3-20 QQYGSSPPYT 10 6 3 1

138 ADI-15920 VH3-48 ARGANYDIWSGFPNWFDP 18 VL2-8 SSYGGSNNVV 10 6 3 1

139 ADI-15797 VH1-18 ARGAVLIWFGEPGGHGLDL 19 VK3-20 QQYGSSLWT 9 6 6 1

140 ADI-15816 VH3-7 ARGDGVFDY 9 VK4-1 QQYYSTPPLYT 11 4 1 1

141 ADI-15786 VH4-30-2 ARGDWLGDYFDY 12 VL3-19 NSRDSSGNHVV 11 4 3 1

142 ADI-15949 VH3-11 ARGEGFRELLVKDYYGMDV 19 VK1-12 QQANSFAWT 9 2 5 1

143 ADI-15961 VH1-3 ARGEIPLLVPPAMVRGFYYYMDV 23 VK4-1 HQYYITPWT 9 5 3 1

144 ADI-16000 VH4-34 ARGERFLEWSLANYYVDV 18 VL1-47 AAWDDSLSGPV 11 13 5 1

145 ADI-16050 VH4-34 ARGETVRLDP 10 VL3-19 NSRDISGNPLVV 12 4 3 1

146 ADI-15754 VH3-64 ARGGAVAGPLYADWYFDL 18 VK3-15 QQYDKWPPWT 10 10 3 1

147 ADI-16015 VH3-33 ARGGDIVVPAGSMDYYGMDV 20 VK1-17 LQHNSYPRT 9 4 1 1

148 ADI-15746 VH3-23 ARGGEMATSSWGYGYYYYYMDV 22 VK1-5 QQYNSYQYT 9 6 4 1

149 ADI-15892 VH3-48 ARGGLDIGVVIAATAFDI 18 VK3-20 QQYGSSLPYT 10 5 1 1

150 ADI-15862 VH4-34 ARGGLSIPMLRGVQPFDF 18 VK3-20 QHYGSSPPYT 10 1 3 1

151 ADI-16021 VH3-33 ARGGSRGLEMATIYGGGLIY 20 VK3-15 QQYNNRPPWT 10 7 1 1

152 ADI-16024 VH1-2 ARGGVVDILTLTFYYAMDV 19 VL2-14 CSYTSSRKLV 10 7 3 1

153 ADI-15960 VH3-48 ARGGYQDDLLVLVTPYDF 18 VK1-5 QQYKTYPYT 9 4 11 1

154 ADI-15734 VH4-34 ARGKSSTVVSRTTHFDY 17 VK2-28 MQALQAPFT 9 6 6 1

155 ADI-16058 VH1-3 ARGLEDTVVVQELNWFDP 18 VK3-20 QQYGGSPPWT 10 3 2 1

156 ADI-15923 VH3-48 ARGLLSSSMISIINEGFDY 19 VK1-5 QRYNSYPWT 9 9 4 1

157 ADI-15829 VH4-31 ARGLSLGHCTGGLCFTQVGGDYNYYGMDV 29 VK1-39 QQSYTTPPT 9 10 5 1

158 ADI-15753 VH5-51 ARGLVAAPGSMSDWFDP 17 VK4-1 QQYYSPPQT 9 6 1 1

159 ADI-16020 VH1-2 ARGNFGRDLLLPAALGGWFDP 21 VK3-15 QQYDTWVT 8 13 2 1

160 ADI-16055 VH3-48 ARGNGDERAVYYYYGMDV 18 VK1-39 QQTYRTPYT 9 9 5 1

161 ADI-15932 VH3-48 ARGNVPPDMLYYYYAMDV 18 VK1-39 QQTYSSPWT 9 13 11 1

162 ADI-16054 VH1-2 ARGPAADCTGGVCFFLERSDAFDI 24 VL1-44 AAWDDSLSGNV 11 4 4 1

163 ADI-15989 VH1-2 ARGPGITMLLLAHRYEFDY 19 VL2-14 SSYTSSSTRV 10 0 3 1

164 ADI-15833 VH3-48 ARGPISRGLLFIDYGMDV 18 VK3-15 QQFNNWPRT 9 6 0 1

165 ADI-15987 VH1-2 ARGPITNYVVINAYDYYMDV 20 VK1-39 QQSYTTPYT 9 4 7 1

166 ADI-15963 VH4-34 ARGPIVVMVFVARPFDY 17 VK1D-17 LQHDSYPYT 9 9 5 1

167 ADI-16040 VH4-34 ARGPMTTVTTWGIGYYDYGMDV 22 VK3-15 QQYKNWPRT 9 6 3 1

168 ADI-15755 VH3-30 ARGPQEFSWLAAVGTVDS 18 VK1-5 QHYKSYPWT 9 2 2 1

169 ADI-15918 VH4-34 ARGPQSFYDLLTGLNPPDS 19 VK3-20 HQYGVSPWT 9 4 3 1

170 ADI-16018 VH4-34 ARGPRRFGILIAHNWFDP 18 VL2-11 CSYGGSYTWV 10 5 8 1

171 ADI-15990 VH4-59 ARGQRRDDYNLWLIRVNDAFDM 22 VK1-5 QQYNSYSPYT 10 5 4 1

172 ADI-16026 VH4-34 ARGRGGDIVIPHDAVGGMDV 20 VK3-11 QLRSHWPPRYT 11 7 4 1

173 ADI-15773 VH5-51 ARGRGQEFTTVLVVVTPYFDV 21 VK1-5 HQYNSYPYT 9 7 2 1

174 ADI-15798 VH3-48 ARGRNDYVWGSFRRDYYYYMDV 22 VK2-28 MQALQTPPA 9 8 0 1

175 ADI-15783 VH4-34 ARGRRNIWLVPNYSVDV 17 VK2-28 MQTLQTPRT 9 3 3 1

176 ADI-15947 VH4-34 ARGRSSTVVSRTTHFDY 17 VK2-28 MQAQQTPIT 9 9 6 1

177 ADI-15985 VH4-34 ARGRVGPEILVPAAAGHYMDV 21 VK3-20 QQYGSSLT 8 5 3 3

178 ADI-15749 VH4-34 ARGRVHSTSVIYHFYGMDV 19 VK1-5 QQYNSYPYT 9 6 5 1

179 ADI-15844 VH4-34 ARGSGTYYYDSGGYYRDAYDI 21 VK3-11 QQRSNWPRQVT 11 6 6 1

180 ADI-15793 VH4-34 ARGSHAYYDILTGPKPFDY 19 VK3-20 QHFGSSPWT 9 4 4 1

181 ADI-16032 VH3-11 ARGSYCTGVLCTHDAFDI 18 VK1-5 QQYKSYSWT 9 8 1 1

182 ADI-16063 VH4-34 ARGTYKDIGVLIAATYYDH 19 VL3-21 QVWVSSSDHRV 11 7 1 1

183 ADI-15752 VH4-34 ARGVAFLSDSSGYPVLFLVGPGFDY 25 VK1-6 LQDYNYPRT 9 3 1 1

184 ADI-15806 VH4-39 ARGVRREFSNILTSYSHFAY 20 VL3-21 QVWDSSRDLWV 11 4 6 1

185 ADI-16022 VH3-33 ARGWSYVDY 9 VK1-17 LQHNSYPYT 9 6 0 1

186 ADI-15807 VH1-46 ARGWWDPEDIVLLPAAPWFDP 21 VL2-23 CSYAGSSTSV 10 6 1 1

187 ADI-15943 VH4-34 ARHAHSGMDV 10 VK2-28 MQALQPPIT 9 4 0 1

188 ADI-15875 VH5-10-1 ARHEGGAFSGLILTGYYQPLDY 22 VK3-20 QQYGSSPLA 9 3 0 1

189 ADI-15805 VH1-3 ARHFPLYFGSGNYSYYMDV 19 VK1-39 QQSYSSPQT 9 4 3 1

190 ADI-15802 VH5-10-1 ARHGYFDWLFLPHYYYAMDV 20 VK1-33 QQYDNLLLT 9 6 4 1

191 ADI-16017 VH4-39 ARHGYGDYLLTHYHFGLDV 19 VK3-20 QQYGSSPPYT 10 6 0 1

192 ADI-16041 VH4-59 ARHHPWGLHGGYGAYNLGWFVP 22 VK1-5 QQYNSYSET 9 8 2 1

193 ADI-15740 VH3-48 ARHNSGLSGGGILYDYVWGSPLDY 24 VK3-15 QQYNDWPRT 9 3 0 1

194 ADI-15865 VH4-39 ARHRALLVVAYFDY 14 VK3-15 QQYNYWPPWT 10 4 3 1

Table S2 (continued). Antibody sequencing.Lineage# Clonename VHGermline CDRH3 CDRH3Length VLGermline VLCDR3 CDRL3Length




195 ADI-16051 VH5-10-1 ARHTYNSDWGTANIAMDV 18 VK3-20 QQYGSSPSWT 10 7 2 1

196 ADI-15991 VH1-18 ARHVWANQWLAENYYYYYMDV 21 VK3-20 QQYGSSRYT 9 0 2 1

197 ADI-15887 VH4-59 ARISPITIFGVVTQGFYYFMDV 22 VL2-14 SSYTSSSTQGFV 12 0 3 1

198 ADI-15852 VH3-7 ARKGQWGGWSWFDP 14 VK1-39 QQSDSTPIT 9 5 6 1

199 ADI-15903 VH3-48 ARKRGIYGLLIGPEDDAFDI 20 VK1-39 QQTYRTPPGT 10 7 4 1

200 ADI-15869 VH2-5 ARKRVDQGGEFDIFTGYYDSWFDP 24 VK3-11 QQRSSWPIT 9 1 3 1

201 ADI-15976 VH4-59 ARLGRLITGTLWYSDY 16 VK3-11 QQRSNWPPTWT 11 3 1 1

202 ADI-15789 VH3-7 ARLGTEWFRDLLYYDYGLDV 20 VK3-15 QQYNKRLLFT 10 5 1 1

203 ADI-16048 VH4-39 ARLKSTDNDFWNGYPDY 17 VK1-6 LQDYNYPPT 9 4 8 1

204 ADI-15973 VH4-30-4 ARLLWGSMRFLEWSPSGYFDS 21 VK3-20 QQYGSSPMT 9 12 2 1

205 ADI-16034 VH4-4 ARLNSITLVRGVEGYYYMDV 20 VK1-39 QQTYSTPRT 9 3 7 1

206 ADI-16043 VH3-23 ARLQRFSFTMGVVVITEPAFDL 22 VK2-28 MQALQTPYA 9 10 0 1

207 ADI-15884 VH4-4 ARLSTSYYDFWSATEFDP 18 VL3-1 QAWDSRIVV 9 1 10 1

208 ADI-16044 VH1-69 ARLVWDIVILPGSTAYYYMDV 21 VK3-20 QQYDSSHT 8 6 1 1

209 ADI-15801 VH4-39 ARPGTTVTTSWGTGYYYYMDV 21 VK3-20 QQHGSAPPYN 10 13 1 1

210 ADI-15940 VH3-21 ARPITILQGVLIVDAFDI 18 VK1-39 QQSYSTLFT 9 8 3 1

211 ADI-15748 VH5-51 ARQAREEYYDFWRGYYSSPFDI 22 VK3-15 QQYNTWPPLT 10 3 2 1

212 ADI-15900 VH4-39 ARQDVVVWARELLHSLGGWFDP 22 VK3-20 QQYGSSALT 9 7 1 1

213 ADI-15815 VH4-4 ARQVVLLGFGDLLYRNTCFDP 21 VK3-20 QQYGSSPPVT 10 1 4 1

214 ADI-15873 VH4-39 ARQYSSGWSWGWFDP 15 VK3-11 QQRTNWPT 8 0 2 1

215 ADI-15859 VH5-51 ARRDFWSGTEY 11 VK3-15 QQYDNWPPWT 10 12 0 1

216 ADI-15930 VH5-10-1 ARRDVLDISPWLHPADWFDP 20 VK1-39 QQSYSTPPEYT 11 12 6 1

217 ADI-16057 VH4-39 ARRFMITFGGVIVEHDAFDI 20 VK1-39 QQTYSTPFT 9 4 6 1

218 ADI-15908 VH4-34 ARRLQRHGNYVGSFDY 16 VK2-28 MQALQAPVT 9 2 4 1

219 ADI-15790 VH4-34 ARRQERHGGYVGFFDY 16 VK2-28 MQALQTPIT 9 46 5 1

220 ADI-15891 VH4-39 ARRVVVVVAGILLESDYFDY 20 VK1-39 QQSYTTLWT 9 0 3 1

221 ADI-15894 VH4-39 ARSFMITFGGVLVEHDAFDI 20 VK1-39 QQSYRTPLMYT 11 3 3 1

222 ADI-15911 VH3-7 ARSKTYYYDSSGYYWFDY 18 VK1-17 LQHNSYPHA 9 9 2 1

223 ADI-15871 VH1-2 ARSQYKWNYFPTPIDY 16 VK1-5 QQYNSYASFT 10 12 0 2

224 ADI-15950 VH4-34 ARSRDYDFWTGHSRFFDY 18 VK3-11 QQRSNWPPLT 10 6 0 1

225 ADI-15822 VH1-2 ARSRFNWNYFPTPIDY 16 VK1-5 QQYNSYPSFT 10 19 2 1

226 ADI-15957 VH3-23 ARSSELSGSYYLQAFDYFDY 20 VK1-39 QQSYSAPRWT 10 3 5 1

227 ADI-16027 VH1-18 ARSVLRYSDWLLYDADYMDV 20 VK1-39 QQTYSTPQVT 10 7 6 1

228 ADI-15787 VH3-48 ARTDPPRGGMVLYAEEWFDP 20 VK1-39 QQSYSTPNT 9 1 3 1

229 ADI-15906 VH3-48 ARTGQPSDWLLPPEYFQH 18 VL3-21 QVWDSSSDHGV 11 4 8 1

230 ADI-15936 VH3-21 ARTLGDSLLYLDAFDI 16 VK3-15 QQYNNRPPWT 10 5 1 1

231 ADI-15779 VH2-70 ARTMYYYGSGSYTDY 15 VK1-39 QQNYSA 6 2 2 1

232 ADI-15914 VH4-39 ARTVPPDVKIKDILVLVAATEGWFDP 26 VK3-20 QQYGSSPLT 9 3 1 1

233 ADI-15913 VH1-69 ARVAGASGSGY 11 VL1-40 QSYDSSLRDNWV 12 1 3 1

234 ADI-15962 VH3-11 ARVAHGYDSYYFDH 14 VK3-20 QQYGSSPLT 9 7 2 1

235 ADI-15760 VH1-18 ARVAPPLMILADLGLDP 17 VK1-13 QHFNDYPQLT 10 9 5 1

236 ADI-15965 VH3-48 ARVDSYYGILTGYPDY 16 VK1-17 LQHNNYPWT 9 6 0 1

237 ADI-15771 VH3-7 ARVGALLWFRDLLFIDYGMDV 21 VK1-39 QQSYSTPGT 9 2 1 2

238 ADI-15890 VH1-18 ARVGGGFGELLYLGVASHDY 20 VK1-6 LQDYNFPWT 9 10 4 1

239 ADI-15919 VH3-33 ARVGSYGSGPLLYSFYYMDV 20 VK1-39 QQSYHPQIT 9 11 7 1

240 ADI-15972 VH4-31 ARVPGARIGITFDI 14 VK1-5 QQYNSHST 8 3 1 1

241 ADI-15994 VH3-48 ARVPYYGILTAGYFDY 16 VK3-20 QQYGSSPLIT 10 4 2 1

242 ADI-15953 VH4-61 ARVQSPFNWNGYYSSLFFDY 20 VL3-25 QSADSSTTLPRCV 13 4 1 1

243 ADI-15958 VH4-34 ARVSLYFGYYMDV 13 VK3-20 QQYGSSSLVT 10 3 2 1

244 ADI-15757 VH1-2 ARVSRGDPYNYDSSGYYGAFDY 22 VK4-1 QQYYTNPWT 9 1 0 1

245 ADI-15879 VH3-53 ARVTRGYSYGWADY 14 VK3-11 QQRSNWPYT 9 3 1 1

246 ADI-15813 VH3-30 ARWGGNIYGSLGLDV 15 VK3-15 QQYNHWWT 8 11 2 1

247 ADI-15982 VH4-59 ARYYYDSRGYYSHYYHMDV 19 VK1-39 QQSYSSQ 7 3 3 1

248 ADI-15747 VH3-66 ASASPADSSGWGLAYYFYMDV 21 VK3-20 QQYGGSLWT 9 6 4 1

249 ADI-15849 VH3-21 ASEEITIFGVLFHPVMDV 18 VK3-20 QQYGSSPRT 9 8 0 1

250 ADI-15812 VH4-4 ASEYYGSGTYGV 12 VL3-19 NSRDSSEKV 9 5 2 1

251 ADI-15788 VH1-2 ASGITILGILMHDAFDI 17 VK3-20 QQYGSSPYT 9 9 3 1

252 ADI-16016 VH3-48 ASGLRDLGVLLVPADYDGMDV 21 VK2-28 MQALQTPRT 9 13 0 1

253 ADI-15775 VH1-69 ASGRTISGVLITDYFIF 17 VK1-5 QQYKSNSRWT 10 7 3 1

254 ADI-15776 VH3-21 ASLLELGSYHYGMDV 15 VK2-28 MQALQIIT 8 5 5 1

255 ADI-15917 VH1-2 ATIGPVSIFEVLIPQNYYYYAMDV 24 VK1-16 QQYDSNPPT 9 4 5 1

256 ADI-15942 VH4-4 ATNRGLTFGELLFRDRGEAFDI 22 VK1-33 QQYDNLPPYT 10 1 0 1

257 ADI-15983 VH1-2 ATPAPIVGATRGYYYHYYGMDV 22 VK2-28 MQALQTPT 8 2 1 1

258 ADI-15998 VH3-21 ATQLVVGGYYYGMDV 15 VK2-28 MQALQTPYT 9 2 2 1

259 ADI-16045 VH3-30 ATRRFRELLERYDYYGLDV 19 VK1-33 QQCDNLPLT 9 11 2 1

260 ADI-15888 VH4-30-4 ATSKTISGVVATYYFDD 17 VK1-5 QQYNSYPWT 9 16 5 1

261 ADI-15997 VH1-24 ATVPPSTIFGVLIKGAQYNWFDP 23 VK3-11 QHRSNWRVT 9 5 7 1

262 ADI-15893 VH5-10-1 AVATAGNLYYYYHMDV 16 VK3-11 QQRTNWPPLT 10 7 0 1

263 ADI-16012 VH1-3 GRDHVALLSAIFEPQYWIDP 20 VK3-11 QHRSNWPPT 9 13 1 1

264 ADI-16052 VH3-49 IRDVST 6 VK2-30 MQGTHWPWA 9 7 1 1

265 ADI-15795 VH3-15 ITENYDFWSAYYRHYYYGMDV 21 VL1-40 QSYDSSLSDNWV 12 5 1 1

266 ADI-15855 VH3-23 MAWGGNYPKDAFDI 14 VK1-39 QQSYLGIT 8 5 4 1

267 ADI-15796 VH3-74 SRGFEDTTLVAFAVSGYHF 19 VK1-33 QQYGNLPLT 9 1 1 1

268 ADI-15830 VH3-15 STDQLLTHSDFMTGYYRGFDY 21 VK3-11 QQRGDWPPLT 10 10 3 1

269 ADI-15934 VH3-15 TADSIAGLPAAIE 13 VL1-40 QSYDSSLRDHWV 12 5 2 1

270 ADI-16033 VH3-23 TKEFQARLFELLVPASGVSYYGLDV 25 VK1-39 QQSYSIPLT 9 1 3 1

271 ADI-15952 VH4-34 TKVGSWNVGGMAFHI 15 VK3-11 QQRSHWPPRIT 11 5 6 1

272 ADI-15853 VH4-4 TRDAVAASWGFSYGVDV 17 VL1-44 AAWDDILNGFRV 12 2 2 2

273 ADI-15750 VH3-49 TRDGFRGSSWGYSYYGMDV 19 VL1-44 AAWDDSLNGPV 11 4 4 1

274 ADI-15731 VH3-49 TRDREQTWFGELASSPLDY 19 VK1-39 QQSYNTPWT 9 5 4 1

275 ADI-15926 VH3-30 TRGGDIVVLVAESRQEDYNGMDV 23 VK1-17 LQHNSYPRT 9 7 1 1

276 ADI-16002 VH3-33 TRGVRGNYVTDDAFDI 16 VK2-30 MQGTYWPPT 9 1 0 1

277 ADI-15810 VH1-46 TRRGIDRSGYYCDY 14 VK2-40 MQRIEFPST 9 4 1 1

278 ADI-15898 VH3-15 TTDHLAVYDDFLTGYYDIDY 20 VK1-17 LQKRSFAYT 9 1 5 1

279 ADI-16001 VH3-15 TTDLWQPGSYYYYMDV 16 VK4-1 LQFYNTPRT 9 6 2 1

280 ADI-15814 VH3-15 TTDSPRVGI 9 VL1-40 QSYDSSLSDNWV 12 0 0 1

281 ADI-15765 VH3-15 TTDSPYSYTFP 11 VL1-40 QSYDARLRDIWV 12 8 4 1

282 ADI-15824 VH3-15 TTNGYDSSGYYSSL 14 VL1-40 QSYDSSLRDSAV 12 5 3 1

283 ADI-15946 VH3-15 TTYTEDMRYFDWLLRGGETFDY 22 VK1-39 QQSYSTPGRYT 11 3 8 1

284 ADI-15851 VH4-31 VASFRTVVTPHI 12 VK3-20 QQYGTSPLT 9 13 0 1

285 ADI-15992 VH3-64D VKDLEGSPYIQLWLLGY 17 VK3-15 LQYNNWPPYT 10 6 2 1

286 ADI-15979 VH3-64D VKGGGTTEYYYYGMDV 16 VK2-30 MQGTHWPYT 9 7 3 1

287 ADI-15745 VH3-64D VKLTIGAARVTGYYFDY 17 VK3-11 QQRSNWPRLT 10 1 0 1

288 ADI-15882 VH3-48 VREGPTHYDIFYYYMDV 17 VL3-19 NSRDSSGNHPWV 12 11 4 1

289 ADI-16005 VH4-34 VRGPPGWYSSDWPIDY 16 VK1-33 QQYDNLPRT 9 4 4 1

290 ADI-15933 VH3-33 VRGWDHVDY 9 VK1-17 LQHNSYPYT 9 11 3 1

291 ADI-15866 VH5-51 VRHPSLFLHSENDFIAAGRTGWFDP 25 VK3-15 QQYNDWPPVYT 11 5 1 3

292 ADI-15944 VH4-59 VRHYSDFWSGYHTPIWFDP 19 VK1-39 QQSYSNLYT 9 3 8 1

293 ADI-15736 VH3-30 VTGGDLVVLPASMDYYGMDV 20 VK1D-17 LQHNTYPYT 9 10 3 1

294 ADI-16046 VH3-15 VTPPVGPHQYYVY 13 VL1-40 QSYDSSLSDHWV 12 4 5 1

Table S3. Binding properties of anti-GP IgGs.

Clone name VH Germline VH CDR3 IgG KD (M)* kon (1/Ms) koff (1/s)† IgG KD (M)* kon (1/Ms) koff (1/s)† IgG KD (M)* kon (1/Ms) koff (1/s)†

ADI-15731 VH3-49 TRDREQTWFGELASSPLDY 5.03E-09 3.98E+04 2.00E-04 7.35E-09 3.71E+04 2.73E-04 4.50E-10 4.44E+05 2.00E-04ADI-15732 VH3-30 AKGGVLIAIINYFDY 3.24E-09 1.75E+05 5.68E-04 2.00E-09 2.06E+05 4.12E-04 N.B.ADI-15733 VH3-21 ARALSMGELFVAGTIDY W.B. N.B. 1.08E-09 1.85E+05 2.00E-04ADI-15734 VH4-34 ARGKSSTVVSRTTHFDY 1.95E-09 1.03E+05 2.00E-04 5.82E-09 8.98E+04 5.23E-04 N.B.ADI-15735 VH3-15 AAGPIKEYHDFLTGYYEVDY W.B. 4.41E-08 1.56E+04 6.86E-04 6.02E-10 3.33E+05 2.00E-04ADI-15736 VH3-30 VTGGDLVVLPASMDYYGMDV W.B. 7.03E-08 2.29E+04 1.61E-03 7.90E-10 2.53E+05 2.00E-04ADI-15737 VH3-21 AREGITLGGVLVINALDI 1.48E-08 1.35E+04 2.00E-04 3.56E-08 2.61E+04 9.28E-04 6.44E-10 3.60E+05 2.31E-04ADI-15738 VH3-30 AREGAVRLDYNILTGYYLSSFDI W.B. N.B. 1.03E-09 1.94E+05 2.00E-04ADI-15739 VH1-2 ARAEVLGLVEQLMEFNWFDP W.B. N.B. 3.10E-09 9.25E+04 2.87E-04ADI-15740 VH3-48 ARHNSGLSGGGILYDYVWGSPLDY W.B. 3.35E-08 5.20E+04 1.74E-03 1.47E-09 2.41E+05 3.55E-04ADI-15741 VH4-4 ARDPGRGRDYYEMDV 1.53E-09 1.31E+05 2.00E-04 1.65E-09 1.25E+05 2.06E-04 N.B.ADI-15742 VH3-23 AKDHRVWAPGYYFDH W.B. 4.82E-09 4.16E+04 2.01E-04 N.B.ADI-15743 VH4-34 ARALPRGGNYRTFDY 1.04E-09 1.93E+05 2.00E-04 1.19E-09 2.22E+05 2.64E-04 N.B.ADI-15744 VH1-3 ARAPDDSIGMLTAYGPLDH 1.49E-08 1.96E+04 2.92E-04 3.33E-08 1.53E+04 5.11E-04 5.19E-10 4.10E+05 2.13E-04ADI-15745 VH3-64D VKLTIGAARVTGYYFDY 9.73E-08 1.46E+04 1.42E-03 4.45E-08 1.59E+04 7.07E-04 N.B.ADI-15746 VH3-23 ARGGEMATSSWGYGYYYYYMDV W.B. N.B. 1.66E-09 1.44E+05 2.39E-04ADI-15747 VH3-66 ASASPADSSGWGLAYYFYMDV W.B. N.B. 1.50E-09 1.33E+05 2.00E-04ADI-15748 VH5-51 ARQAREEYYDFWRGYYSSPFDI 9.36E-09 3.26E+04 3.05E-04 3.58E-09 5.59E+04 2.00E-04 N.B.ADI-15749 VH4-34 ARGRVHSTSVIYHFYGMDV 1.44E-08 2.78E+04 4.00E-04 1.44E-08 4.94E+04 7.09E-04 7.52E-10 2.66E+05 2.00E-04ADI-15750 VH3-49 TRDGFRGSSWGYSYYGMDV W.B. 4.18E-09 5.62E+04 2.35E-04 9.32E-10 2.15E+05 2.00E-04ADI-15751 VH3-23 AKGYDFWSAYPDY W.B. 1.98E-09 1.01E+05 2.00E-04 3.24E-10 6.17E+05 2.00E-04ADI-15752 VH4-34 ARGVAFLSDSSGYPVLFLVGPGFDY 5.64E-09 3.55E+04 2.00E-04 1.42E-08 4.02E+04 5.71E-04 5.63E-10 3.56E+05 2.00E-04ADI-15753 VH5-51 ARGLVAAPGSMSDWFDP 5.24E-09 3.82E+04 2.00E-04 3.10E-09 6.46E+04 2.00E-04 N.B.ADI-15754 VH3-64 ARGGAVAGPLYADWYFDL 7.19E-09 2.78E+04 2.00E-04 4.70E-09 4.62E+04 2.17E-04 5.57E-10 3.59E+05 2.00E-04ADI-15755 VH3-30 ARGPQEFSWLAAVGTVDS 7.58E-09 2.64E+04 2.00E-04 3.27E-09 6.11E+04 2.00E-04 7.86E-10 4.64E+05 3.65E-04ADI-15756 VH1-18 ARDGFSDIGMVEFYYYGMDV 7.60E-09 2.63E+04 2.00E-04 4.82E-09 4.15E+04 2.00E-04 7.50E-10 2.67E+05 2.00E-04ADI-15757 VH1-2 ARVSRGDPYNYDSSGYYGAFDY 2.02E-09 9.90E+04 2.00E-04 2.90E-09 6.91E+04 2.00E-04 N.B.ADI-15758 VH1-46 ARDRYPTVVNYFGMDV 7.77E-10 2.58E+05 2.00E-04 8.72E-10 2.29E+05 2.00E-04 N.B.ADI-15759 VH1-46 ARDLMGWQHNLGGFDY 6.32E-09 3.17E+04 2.00E-04 5.59E-09 5.64E+04 3.15E-04 N.B.ADI-15760 VH1-18 ARVAPPLMILADLGLDP 5.30E-09 3.77E+04 2.00E-04 1.14E-08 4.74E+04 5.39E-04 9.83E-10 5.74E+05 5.64E-04ADI-15761 VH1-18 ARDVEIAVVAVATLSRNFGMDV 5.36E-09 3.73E+04 2.00E-04 4.86E-09 4.11E+04 2.00E-04 8.40E-10 3.43E+05 2.88E-04ADI-15762 VH3-48 ARTLGYCSGGSCYSVSHDAFDI 2.58E-08 1.63E+04 4.20E-04 6.41E-09 3.96E+04 2.54E-04 N.B.ADI-15763 VH1-18 ARARQLLRDLLFAPQGMDV 6.18E-09 3.23E+04 2.00E-04 8.71E-09 5.31E+04 4.63E-04 8.75E-10 2.29E+05 2.00E-04ADI-15764 VH1-3 ARETSKYDILTGPHDYYMDV 4.22E-09 4.74E+04 2.00E-04 3.75E-09 5.33E+04 2.00E-04 3.91E-10 5.11E+05 2.00E-04ADI-15765 VH3-15 TTDSPYSYTFP 2.97E-09 6.74E+04 2.00E-04 1.23E-09 1.62E+05 2.00E-04 3.29E-10 6.08E+05 2.00E-04ADI-15766 VH1-69 ARESEGSGWNPFDY 6.34E-09 3.15E+04 2.00E-04 1.43E-08 4.02E+04 5.75E-04 7.33E-10 2.73E+05 2.00E-04ADI-15767 VH3-23 AKESEWLFLSALDY W.B. 6.54E-09 5.99E+04 3.92E-04 1.31E-09 6.77E+05 8.83E-04ADI-15768 VH3-23 AKVGMTAVTKGMEIDYSYGMDV W.B. 5.63E-09 3.55E+04 2.00E-04 6.35E-10 3.15E+05 2.00E-04ADI-15769 VH3-21 ARAGGSGTSDGMDYYYYSGMDV W.B. N.B. 1.09E-09 1.84E+05 2.00E-04ADI-15771 VH3-7 ARVGALLWFRDLLFIDYGMDV W.B. 6.49E-09 5.18E+04 3.36E-04 1.00E-09 1.99E+05 2.00E-04ADI-15772 VH1-18 ARDLTPRYGMDV 4.55E-09 4.40E+04 2.00E-04 2.97E-09 6.74E+04 2.00E-04 N.B.ADI-15773 VH5-51 ARGRGQEFTTVLVVVTPYFDV 5.94E-09 3.37E+04 2.00E-04 3.77E-09 5.31E+04 2.00E-04 7.75E-10 2.58E+05 2.00E-04ADI-15774 VH3-23 AKEHYYNILTGYLRAHNWFDP W.B. N.B. 3.98E-09 1.81E+05 7.18E-04ADI-15775 VH1-69 ASGRTISGVLITDYFIF 5.10E-09 3.92E+04 2.00E-04 4.91E-09 5.62E+04 2.76E-04 1.59E-09 3.47E+05 5.51E-04ADI-15777 VH1-46 RRSGWSVTDYFDY 8.80E-09 3.31E+04 2.91E-04 3.48E-09 5.74E+04 2.00E-04 N.B.ADI-15778 VH3-48 ARAAADYNYGMDV W.B. 1.05E-08 3.96E+04 4.16E-04 4.59E-10 4.36E+05 2.00E-04ADI-15779 VH2-70 ARTMYYYGSGSYTDY 6.69E-09 5.23E+04 3.50E-04 3.15E-09 1.18E+05 3.71E-04 N.B.ADI-15780 VH1-18 ARDLTPRYGMDV 3.96E-09 5.05E+04 2.00E-04 3.14E-09 6.37E+04 2.00E-04 N.B.ADI-15781 VH5-10-1 AKTFYDTDY 4.18E-08 2.88E+04 1.20E-03 2.80E-08 4.82E+04 1.35E-03 N.B.ADI-15782 VH4-4 ARFTDWYYDILTGKKEDFYYIDV 6.75E-10 2.97E+05 2.00E-04 1.31E-09 3.19E+05 4.19E-04 N.B.ADI-15783 VH4-34 ARGRRNIWLVPNYSVDV 2.04E-09 9.80E+04 2.00E-04 2.20E-09 9.10E+04 2.00E-04 N.B.ADI-15784 VH1-18 ARDLTPRDGMDV 5.42E-09 3.69E+04 2.00E-04 2.51E-09 7.96E+04 2.00E-04 N.B.ADI-15785 VH3-30 AKGTVIIAMLNYFDY 2.28E-09 9.16E+04 2.08E-04 1.64E-09 1.22E+05 2.00E-04 N.B.ADI-15786 VH4-30-2 ARGDWLGDYFDY 6.22E-09 4.59E+04 2.86E-04 6.58E-09 4.99E+04 3.28E-04 N.B.ADI-15787 VH3-48 ARTDPPRGGMVLYAEEWFDP 5.22E-09 3.83E+04 2.00E-04 3.75E-09 5.34E+04 2.00E-04 3.72E-10 5.38E+05 2.00E-04ADI-15788 VH1-2 ASGITILGILMHDAFDI 4.72E-09 4.24E+04 2.00E-04 4.28E-09 4.67E+04 2.00E-04 5.35E-10 3.74E+05 2.00E-04ADI-15789 VH3-7 ARLGTEWFRDLLYYDYGLDV W.B. 4.80E-09 4.57E+04 2.19E-04 7.57E-10 2.64E+05 2.00E-04ADI-15791 VH3-21 ARGDDFLVVAGTIDYSHYVMDV W.B. 3.79E-09 5.28E+04 2.00E-04 5.39E-10 3.71E+05 2.00E-04ADI-15792 VH4-61 ARDREVVPGLSGLLYSFHGMDV 7.27E-09 2.75E+04 2.00E-04 1.19E-08 4.30E+04 5.12E-04 6.20E-10 3.23E+05 2.00E-04ADI-15793 VH4-34 ARGSHAYYDILTGPKPFDY 5.86E-09 3.42E+04 2.00E-04 1.55E-08 4.29E+04 6.65E-04 6.07E-10 3.29E+05 2.00E-04ADI-15794 VH1-69 ARDNSGYDLNPLHY W.B. N.B. 1.31E-09 1.53E+05 2.00E-04ADI-15795 VH3-15 ITENYDFWSAYYRHYYYGMDV W.B. 2.99E-09 6.68E+04 2.00E-04 6.11E-10 3.34E+05 2.04E-04ADI-15796 VH3-74 SRGFEDTTLVAFAVSGYHF W.B. 3.98E-09 5.02E+04 2.00E-04 5.10E-10 3.92E+05 2.00E-04ADI-15797 VH1-18 ARGAVLIWFGEPGGHGLDL 7.29E-09 3.71E+04 2.70E-04 2.98E-09 6.71E+04 2.00E-04 6.04E-10 3.31E+05 2.00E-04ADI-15798 VH3-48 ARGRNDYVWGSFRRDYYYYMDV W.B. 7.47E-09 9.69E+04 7.24E-04 N.B.ADI-15799 VH3-74 ARELTVNYPGSGSSFMVGTYYHYALDV W.B. 4.26E-09 4.69E+04 2.00E-04 5.69E-10 3.52E+05 2.00E-04ADI-15800 VH3-21 AGAEYSYGFGVDAFDI W.B. 4.02E-09 5.45E+04 2.19E-04 3.42E-09 5.36E+05 1.83E-03ADI-15801 VH4-39 ARPGTTVTTSWGTGYYYYMDV W.B. N.B. 1.14E-09 1.76E+05 2.00E-04ADI-15802 VH5-10-1 ARHGYFDWLFLPHYYYAMDV 3.80E-09 5.27E+04 2.00E-04 2.65E-09 7.54E+04 2.00E-04 5.25E-10 6.83E+05 3.59E-04ADI-15803 VH3-53 ARDRLLWFTELLYRDNGMDV W.B. 3.33E-09 6.01E+04 2.00E-04 6.72E-10 2.98E+05 2.00E-04ADI-15804 VH1-46 AIFVLSIGGYQSY 5.61E-09 3.57E+04 2.00E-04 3.20E-09 6.25E+04 2.00E-04 N.B.ADI-15805 VH1-3 ARHFPLYFGSGNYSYYMDV 1.52E-08 5.38E+05 8.19E-03 1.55E-08 3.93E+05 6.10E-03 N.B.ADI-15806 VH4-39 ARGVRREFSNILTSYSHFAY 5.92E-09 3.38E+04 2.00E-04 4.40E-09 4.54E+04 2.00E-04 6.76E-10 2.96E+05 2.00E-04ADI-15807 VH1-46 ARGWWDPEDIVLLPAAPWFDP 6.13E-09 3.26E+04 2.00E-04 1.56E-08 4.75E+04 7.39E-04 1.07E-09 1.86E+05 2.00E-04ADI-15808 VH3-33 ARDGTYYYGSGSEHWDYYGLAV 6.48E-09 3.76E+04 2.43E-04 3.29E-09 6.09E+04 2.00E-04 N.B.ADI-15809 VH2-5 AHIGGKDYYHSFGSYYQTHAFDI 5.52E-09 3.63E+04 2.00E-04 3.66E-09 5.47E+04 2.00E-04 4.77E-10 4.20E+05 2.00E-04ADI-15810 VH1-46 TRRGIDRSGYYCDY 7.58E-09 2.64E+04 2.00E-04 3.79E-09 5.28E+04 2.00E-04 N.B.ADI-15811 VH3-30 AKGRAPVAGTSYFDY 8.05E-08 2.97E+05 2.39E-02 1.97E-08 3.40E+05 6.67E-03 N.B.ADI-15812 VH4-4 ASEYYGSGTYGV 1.39E-08 2.97E+04 4.14E-04 3.74E-09 5.35E+04 2.00E-04 N.B.ADI-15813 VH3-30 ARWGGNIYGSLGLDV W.B. 2.56E-08 4.65E+04 1.19E-03 N.B.ADI-15814 VH3-15 TTDSPRVGI W.B. 1.60E-08 4.60E+04 7.36E-04 1.00E-08 2.27E+05 2.27E-03ADI-15815 VH4-4 ARQVVLLGFGDLLYRNTCFDP W.B. N.B. 1.15E-09 1.74E+05 2.00E-04ADI-15816 VH3-7 ARGDGVFDY 6.04E-09 2.70E+05 1.63E-03 3.27E-09 4.96E+05 1.62E-03 N.B.ADI-15817 VH1-18 ARDSTLLAYSGYDNTIFLHNGMAV 6.53E-09 3.07E+04 2.00E-04 5.08E-09 3.94E+04 2.00E-04 6.18E-10 3.24E+05 2.00E-04ADI-15818 VH3-48 ARTLGYCSGGSCYSVSHDAFDI W.B. 2.32E-09 8.62E+04 2.00E-04 N.B.ADI-15819 VH3-30 AKGGVLIAIINYFDY 1.23E-08 1.33E+05 1.64E-03 4.80E-09 1.73E+05 8.29E-04 N.B.ADI-15820 VH4-59 ARHTPIRYSSGWYLDY 7.72E-10 2.59E+05 2.00E-04 2.40E-09 2.50E+05 6.01E-04 N.B.ADI-15821 VH3-21 AREAWDLDIVATILLDY W.B. 1.16E-08 4.24E+04 4.90E-04 5.52E-10 3.62E+05 2.00E-04ADI-15822 VH1-2 ARSRFNWNYFPTPIDY 9.86E-09 3.27E+04 3.23E-04 1.97E-08 4.29E+04 8.44E-04 N.B.ADI-15823 VH3-23 AKNIGVLAVIYSAEDDAFDM W.B. 3.81E-09 5.25E+04 2.00E-04 3.80E-10 5.27E+05 2.00E-04ADI-15824 VH3-15 TTNGYDSSGYYSSL W.B. 1.86E-09 1.08E+05 2.00E-04 3.45E-10 5.79E+05 2.00E-04ADI-15825 VH3-21 AREGITIFGVLIHPVMDV W.B. 4.92E-09 5.67E+04 2.79E-04 5.03E-10 4.03E+05 2.03E-04

Zaire GP∆TM Zaire GP∆muc Zaire sGP

Table S3 (continued). Binding properties of anti-GP IgGs.



ADI-15826 VH1-18 ARDGQTFYDILTTQWYGMDV 2.70E-08 1.58E+04 4.27E-04 2.14E-08 3.26E+04 6.96E-04 7.15E-10 2.80E+05 2.00E-04ADI-15827 VH3-23 AKPKEGSEWLILRFDAFDV W.B. 1.40E-08 4.33E+04 6.05E-04 5.61E-10 3.57E+05 2.00E-04ADI-15828 VH3-23 AKDLRSWDIVVVPAVHGAFDI W.B. N.B. 8.00E-10 2.50E+05 2.00E-04ADI-15829 VH4-31 ARGLSLGHCTGGLCFTQVGGDYNYYGMDV 7.16E-09 3.75E+04 2.69E-04 6.95E-09 6.14E+04 4.27E-04 5.68E-10 3.52E+05 2.00E-04ADI-15830 VH3-15 STDQLLTHSDFMTGYYRGFDY 9.15E-09 3.30E+04 3.02E-04 3.40E-09 5.88E+04 2.00E-04 3.17E-10 6.31E+05 2.00E-04ADI-15831 VH3-21 ARDLRYFDWLYHDAFDI W.B. 4.00E-09 5.01E+04 2.00E-04 5.06E-10 4.20E+05 2.12E-04ADI-15832 VH3-33 AREPGFCSGGTCFQADYFDY W.B. 2.39E-08 3.44E+04 8.20E-04 8.15E-10 2.45E+05 2.00E-04ADI-15833 VH3-48 ARGPISRGLLFIDYGMDV W.B. 1.15E-08 6.02E+04 6.91E-04 2.52E-09 7.18E+05 1.81E-03ADI-15834 VH1-18 ARDRLLFYHILTASYPFDY 4.99E-09 4.01E+04 2.00E-04 3.38E-09 5.91E+04 2.00E-04 4.95E-10 4.04E+05 2.00E-04ADI-15835 VH1-3 ARDAGPDQLLWLSDYHYMDV W.B. N.B. 9.44E-10 2.12E+05 2.00E-04ADI-15836 VH3-23 AKGANFWGAWSDYYPV W.B. 3.24E-09 1.03E+05 3.33E-04 6.13E-10 6.86E+05 4.20E-04ADI-15837 VH3-23 AKDALTVTTVLWGSDQYYFDY W.B. 2.94E-09 6.79E+04 2.00E-04 3.23E-10 6.20E+05 2.00E-04ADI-15839 VH4-34 ARALPRGGNYRTFEY 1.25E-09 1.60E+05 2.00E-04 9.87E-10 2.03E+05 2.00E-04 N.B.ADI-15841 VH3-30 AKGAVVIAMLNYFDY 9.64E-10 2.07E+05 2.00E-04 7.68E-10 2.61E+05 2.00E-04 N.B.ADI-15842 VH1-46 ARDRAQAGTNNWFDP 1.54E-09 1.46E+05 2.25E-04 1.81E-09 1.16E+05 2.11E-04 N.B.ADI-15843 VH4-34 ARAWLRSRGYPSFDY 2.28E-09 8.79E+04 2.00E-04 2.01E-09 9.95E+04 2.00E-04 N.B.ADI-15844 VH4-34 ARGSGTYYYDSGGYYRDAYDI 9.85E-09 5.07E+05 4.99E-03 1.31E-08 3.48E+05 4.57E-03 N.B.ADI-15845 VH1-2 ARVNYYDSSGYYGWFDP 1.47E-09 1.36E+05 2.00E-04 2.02E-09 9.88E+04 2.00E-04 N.B.ADI-15846 VH4-4 ARDLRAPTFSWTSRLTPKEKNSDN W.B. N.B. 1.78E-09 1.12E+05 2.00E-04ADI-15847 VH3-23 AKSGTVNYYFYYMDV W.B. 1.40E-09 1.43E+05 2.00E-04 N.B.ADI-15848 VH1-46 ARDRYPVLVATDYGMDV 5.96E-10 3.36E+05 2.00E-04 5.19E-10 3.86E+05 2.00E-04 N.B.ADI-15849 VH3-21 ASEEITIFGVLFHPVMDV W.B. 1.68E-09 2.26E+05 3.79E-04 N.B.ADI-15850 VH3-23 AKGSVVVVASTLYYFDY W.B. 2.50E-09 8.01E+04 2.00E-04 N.B.ADI-15851 VH4-31 VASFRTVVTPHI 3.32E-09 6.02E+04 2.00E-04 7.82E-09 5.90E+04 4.61E-04 N.B.ADI-15852 VH3-7 ARKGQWGGWSWFDP 1.42E-08 3.01E+04 4.28E-04 2.41E-09 8.31E+04 2.00E-04 N.B.ADI-15853 VH4-4 TRDAVAASWGFSYGVDV 1.39E-08 1.69E+04 2.34E-04 1.96E-08 4.43E+04 8.66E-04 5.43E-10 3.68E+05 2.00E-04ADI-15854 VH3-21 ARDLGHGVSYGYGTYYDY W.B. 4.22E-09 1.53E+05 6.45E-04 N.B.ADI-15855 VH3-23 MAWGGNYPKDAFDI W.B. 1.95E-09 1.12E+05 2.19E-04 N.B.ADI-15856 VH4-39 ARADMLQGIIITRVAFDY 4.72E-09 4.23E+04 2.00E-04 8.78E-09 5.20E+04 4.57E-04 3.15E-10 6.36E+05 2.00E-04ADI-15858 VH3-48 AREGPTPMDYYYYYMDV W.B. 4.06E-09 4.93E+04 2.00E-04 N.B.ADI-15859 VH5-51 ARRDFWSGTEY 1.38E-08 2.36E+04 3.27E-04 3.42E-09 5.84E+04 2.00E-04 N.B.ADI-15860 VH4-59 ARDPRYYDYFRGSYGHYGLDV 2.26E-09 1.37E+05 3.09E-04 1.43E-08 1.60E+05 2.30E-03 N.B.ADI-15861 VH4-34 ARAWLRSSSYPSFDY 3.04E-09 6.59E+04 2.00E-04 2.25E-09 8.89E+04 2.00E-04 N.B.ADI-15862 VH4-34 ARGGLSIPMLRGVQPFDF 1.14E-08 1.99E+04 2.27E-04 4.12E-09 4.85E+04 2.00E-04 5.54E-10 3.61E+05 2.00E-04ADI-15863 VH3-21 AREGITILGVLIHPVMDV 7.35E-09 2.72E+04 2.00E-04 3.22E-09 6.21E+04 2.00E-04 3.84E-10 5.21E+05 2.00E-04ADI-15864 VH1-18 ARDRGTFTYVSGLVVAAYLDAFDI W.B. 2.74E-08 4.07E+04 1.12E-03 7.83E-10 2.56E+05 2.00E-04ADI-15865 VH4-39 ARHRALLVVAYFDY 1.53E-09 1.30E+05 2.00E-04 1.48E-09 1.35E+05 2.00E-04 N.B.ADI-15866 VH5-51 VRHPSLFLHSENDFIAAGRTGWFDP W.B. N.B. 7.83E-10 2.56E+05 2.00E-04ADI-15867 VH4-30-4 ARDRYNTDYGNVLYYFYGMDV 7.13E-09 2.81E+04 2.00E-04 3.97E-09 5.04E+04 2.00E-04 6.48E-10 3.09E+05 2.00E-04ADI-15868 VH3-33 ARADSTDDYYYYYMDV W.B. 3.92E-09 5.10E+04 2.00E-04 N.B.ADI-15869 VH2-5 ARKRVDQGGEFDIFTGYYDSWFDP 7.18E-09 2.79E+04 2.00E-04 4.37E-09 5.98E+04 2.61E-04 5.50E-10 3.64E+05 2.00E-04ADI-15870 VH1-18 ARDTAFMFASFGVGYHYNGMDV 7.29E-09 3.14E+04 2.29E-04 3.32E-09 6.03E+04 2.00E-04 3.30E-10 6.06E+05 2.00E-04ADI-15871 VH1-2 ARSQYKWNYFPTPIDY 4.46E-09 4.49E+04 2.00E-04 3.78E-09 5.29E+04 2.00E-04 N.B.ADI-15872 VH4-39 ARADMLQGIIITRVAFDY 5.49E-09 3.64E+04 2.00E-04 4.07E-09 4.91E+04 2.00E-04 3.18E-10 6.29E+05 2.00E-04ADI-15873 VH4-39 ARQYSSGWSWGWFDP 4.64E-09 6.56E+04 3.05E-04 8.52E-09 6.33E+04 5.39E-04 N.B.ADI-15874 VH4-39 ARADMLQGIIITRVAFDY 4.93E-09 4.06E+04 2.00E-04 6.84E-09 4.79E+04 3.28E-04 3.18E-10 6.29E+05 2.00E-04ADI-15875 VH5-10-1 ARHEGGAFSGLILTGYYQPLDY 7.25E-09 2.76E+04 2.00E-04 4.56E-09 4.48E+04 2.04E-04 7.63E-10 3.14E+05 2.40E-04ADI-15876 VH3-7 ARDASDFWSPNFDY W.B. 4.36E-09 4.59E+04 2.00E-04 N.B.ADI-15877 VH4-59 ARAAKGCTSTSCYEWDV 3.29E-09 6.09E+04 2.00E-04 2.28E-09 8.76E+04 2.00E-04 N.B.ADI-15878 VH3-23 AKDHRVWAAGYHFDY W.B. 1.72E-09 1.16E+05 2.00E-04 N.B.ADI-15879 VH3-53 ARVTRGYSYGWADY W.B. 3.36E-09 5.95E+04 2.00E-04 N.B.ADI-15880 VH3-7 AREAFLEWLAPLGHYYMDV W.B. N.B. 2.80E-09 4.28E+05 1.20E-03ADI-15881 VH4-31 ARGHSGDYSPPFFDY W.B. N.B. N.B.ADI-15882 VH3-48 VREGPTHYDIFYYYMDV 8.13E-09 2.49E+04 2.03E-04 3.68E-09 5.44E+04 2.00E-04 N.B.ADI-15883 VH3-30 AKAGDYIWGSYRYFAGMLKPFDT W.B. 4.11E-09 7.59E+04 3.12E-04 N.B.ADI-15884 VH4-4 ARLSTSYYDFWSATEFDP 1.39E-08 3.22E+04 4.48E-04 3.07E-09 7.06E+04 2.17E-04 N.B.ADI-15885 VH5-51 VRHPSLFLHSENDFIAAGRTGWFDP W.B. 1.37E-08 4.23E+04 5.79E-04 7.82E-10 2.56E+05 2.00E-04ADI-15886 VH3-53 ARETVFGSQYYGMDV W.B. 4.10E-09 4.88E+04 2.00E-04 N.B.ADI-15887 VH4-59 ARISPITIFGVVTQGFYYFMDV 6.21E-09 3.22E+04 2.00E-04 3.37E-09 5.93E+04 2.00E-04 N.B.ADI-15888 VH4-30-4 ATSKTISGVVATYYFDD 6.66E-09 3.23E+04 2.15E-04 8.45E-09 2.37E+04 2.00E-04 3.98E-10 5.02E+05 2.00E-04ADI-15889 VH1-2 AKAWPTDIVILPDALSGFDA 5.45E-09 3.67E+04 2.00E-04 4.54E-09 4.86E+04 2.21E-04 4.39E-10 5.79E+05 2.54E-04ADI-15890 VH1-18 ARVGGGFGELLYLGVASHDY 6.78E-09 2.95E+04 2.00E-04 2.19E-08 3.73E+04 8.18E-04 5.80E-10 4.40E+05 2.55E-04ADI-15891 VH4-39 ARRVVVVVAGILLESDYFDY 4.58E-09 4.37E+04 2.00E-04 3.42E-09 5.85E+04 2.00E-04 3.55E-10 5.64E+05 2.00E-04ADI-15892 VH3-48 ARGGLDIGVVIAATAFDI W.B. 3.88E-09 5.16E+04 2.00E-04 5.76E-10 4.79E+05 2.76E-04ADI-15893 VH5-10-1 AVATAGNLYYYYHMDV 2.46E-08 1.49E+04 3.68E-04 1.42E-08 5.59E+04 7.93E-04 N.B.ADI-15894 VH4-39 ARSFMITFGGVLVEHDAFDI 2.75E-08 1.26E+04 3.45E-04 7.96E-09 5.14E+04 4.09E-04 6.17E-10 3.24E+05 2.00E-04ADI-15895 VH3-48 AREGPSPSDSYYYYMDV W.B. 2.87E-09 6.97E+04 2.00E-04 N.B.ADI-15896 VH3-33 AKEGFLEWLSPSDYYFGMDV W.B. 7.53E-09 4.95E+04 3.72E-04 5.59E-10 3.58E+05 2.00E-04ADI-15897 VH3-48 ARDRMPKYDILTGPESAGMDV 1.55E-08 2.07E+04 3.20E-04 3.52E-09 5.68E+04 2.00E-04 2.82E-10 7.09E+05 2.00E-04ADI-15898 VH3-15 TTDHLAVYDDFLTGYYDIDY W.B. 3.74E-09 5.35E+04 2.00E-04 4.11E-10 4.87E+05 2.00E-04ADI-15899 VH3-30 AREKRFLEWLSVGDAFDI W.B. 5.36E-09 3.73E+04 2.00E-04 6.26E-10 3.20E+05 2.00E-04ADI-15900 VH4-39 ARQDVVVWARELLHSLGGWFDP W.B. N.B. 1.30E-09 1.53E+05 2.00E-04ADI-15901 VH4-59 ARHTPIRYSSGWYLDY 8.04E-10 2.49E+05 2.00E-04 2.90E-09 2.32E+05 6.72E-04 N.B.ADI-15902 VH3-21 ARAVGELLFYTDAFDI W.B. 4.52E-09 6.17E+04 2.79E-04 3.19E-09 4.79E+05 1.53E-03ADI-15903 VH3-48 ARKRGIYGLLIGPEDDAFDI W.B. 2.73E-09 7.34E+04 2.00E-04 2.36E-10 8.49E+05 2.00E-04ADI-15904 VH3-30 ARDFWLLLDAFDI W.B. 1.45E-08 4.15E+04 6.02E-04 4.96E-10 4.04E+05 2.00E-04ADI-15906 VH3-48 ARTGQPSDWLLPPEYFQH W.B. N.B. 9.72E-10 2.49E+05 2.42E-04ADI-15907 VH3-30 ARENYGDDTLILVGSYYGMDV W.B. 4.35E-09 5.52E+04 2.40E-04 5.04E-10 3.97E+05 2.00E-04ADI-15908 VH4-34 ARRLQRHGNYVGSFDY 1.59E-09 1.26E+05 2.00E-04 1.26E-09 1.59E+05 2.00E-04 N.B.ADI-15909 VH6-1 AREWELRYDAFDI 1.08E-09 2.38E+05 2.56E-04 1.16E-09 2.44E+05 2.83E-04 N.B.ADI-15910 VH3-7 AREAFLEWLAPLGYYYMDV W.B. 6.33E-09 6.01E+04 3.80E-04 1.31E-09 2.93E+05 3.84E-04ADI-15911 VH3-7 ARSKTYYYDSSGYYWFDY W.B. 1.62E-09 2.19E+05 3.54E-04 N.B.ADI-15912 VH4-34 ARAWLRSRGYPSFDY 1.35E-09 1.48E+05 2.00E-04 1.23E-09 1.63E+05 2.00E-04 N.B.ADI-15913 VH1-69 ARVAGASGSGY W.B. 1.58E-08 4.64E+04 7.33E-04 2.99E-09 2.71E+05 8.11E-04ADI-15914 VH4-39 ARTVPPDVKIKDILVLVAATEGWFDP 6.20E-09 3.23E+04 2.00E-04 4.50E-09 4.44E+04 2.00E-04 4.05E-10 4.94E+05 2.00E-04ADI-15915 VH3-21 ARDIYDSGGYYYGGGTDAFDI W.B. 5.02E-09 5.06E+04 2.54E-04 N.B.ADI-15916 VH3-30 AKGAVVIAMLNYFDY 9.09E-10 2.20E+05 2.00E-04 6.51E-10 3.07E+05 2.00E-04 N.B.ADI-15917 VH1-2 ATIGPVSIFEVLIPQNYYYYAMDV 6.69E-09 2.99E+04 2.00E-04 7.25E-09 4.72E+04 3.42E-04 5.42E-10 3.69E+05 2.00E-04ADI-15918 VH4-34 ARGPQSFYDLLTGLNPPDS 6.34E-09 3.15E+04 2.00E-04 3.95E-09 5.07E+04 2.00E-04 4.44E-10 4.51E+05 2.00E-04ADI-15919 VH3-33 ARVGSYGSGPLLYSFYYMDV W.B. 1.35E-08 5.12E+04 6.92E-04 4.96E-10 4.03E+05 2.00E-04ADI-15920 VH3-48 ARGANYDIWSGFPNWFDP W.B. 3.66E-09 5.46E+04 2.00E-04 3.36E-10 5.95E+05 2.00E-04ADI-15921 VH1-46 ARDNPGDQWLVPYNSYYYMDV 6.68E-09 3.10E+04 2.07E-04 2.24E-08 4.36E+04 9.74E-04 1.62E-09 2.95E+05 4.78E-04




ADI-15922 VH1-69 AREETIGGIVVSQFFDP W.B. 2.72E-08 4.53E+04 1.23E-03 5.95E-10 3.36E+05 2.00E-04ADI-15923 VH3-48 ARGLLSSSMISIINEGFDY 4.70E-09 4.25E+04 2.00E-04 9.69E-09 2.93E+04 2.84E-04 5.29E-10 3.78E+05 2.00E-04ADI-15924 VH3-30 AKESFSGRQLLVPWSFDF W.B. 6.62E-09 9.74E+04 6.44E-04 1.02E-09 1.97E+05 2.00E-04ADI-15925 VH3-30 AKGAVVIAMLNYFDS 9.84E-10 2.03E+05 2.00E-04 8.83E-10 2.27E+05 2.00E-04 N.B.ADI-15926 VH3-30 TRGGDIVVLVAESRQEDYNGMDV 4.88E-09 4.10E+04 2.00E-04 2.57E-08 3.06E+04 7.84E-04 6.76E-10 2.96E+05 2.00E-04ADI-15927 VH1-46 ALLAGYSGFYYLVPFDY 5.25E-09 3.81E+04 2.00E-04 N.B. 9.77E-10 2.05E+05 2.00E-04ADI-15928 VH4-4 ARERLLWLKNLLYNENGLDV 5.25E-09 3.81E+04 2.00E-04 3.76E-08 2.11E+04 7.94E-04 6.41E-10 3.12E+05 2.00E-04ADI-15929 VH3-21 ARDAPITSSWGTGYYDYYYMDV W.B. N.B. 8.76E-10 2.28E+05 2.00E-04ADI-15930 VH5-10-1 ARRDVLDISPWLHPADWFDP 6.78E-09 2.95E+04 2.00E-04 4.68E-08 1.59E+04 7.44E-04 6.78E-10 2.95E+05 2.00E-04ADI-15931 VH3-7 ARVGALLWFRDLLFIDYGMDV W.B. N.B. 1.10E-09 1.81E+05 2.00E-04ADI-15932 VH3-48 ARGNVPPDMLYYYYAMDV 5.11E-09 3.92E+04 2.00E-04 1.98E-08 2.89E+04 5.71E-04 5.31E-10 3.77E+05 2.00E-04ADI-15933 VH3-33 VRGWDHVDY 3.23E-09 6.20E+04 2.00E-04 2.86E-09 8.16E+04 2.34E-04 N.B.ADI-15934 VH3-15 TADSIAGLPAAIE W.B. 1.46E-08 2.98E+04 4.35E-04 1.29E-09 1.55E+05 2.00E-04ADI-15935 VH1-18 ARDLTPRYGLDV 1.15E-09 1.75E+05 2.00E-04 1.56E-09 1.28E+05 2.00E-04 N.B.ADI-15936 VH3-21 ARTLGDSLLYLDAFDI W.B. N.B. 7.48E-10 2.67E+05 2.00E-04ADI-15937 VH1-18 ARDVLRFLEWLLHLRTNDYNGMDV 6.80E-09 3.24E+04 2.20E-04 N.B. 6.98E-10 2.87E+05 2.00E-04ADI-15938 VH4-34 ARGAGIIFGGVVLTNNNWGDV 7.05E-09 2.84E+04 2.00E-04 N.B. 8.18E-10 2.45E+05 2.00E-04ADI-15939 VH3-23 AKVEGEWSDIVVVVAATPFDY W.B. N.B. 1.13E-09 1.78E+05 2.00E-04ADI-15940 VH3-21 ARPITILQGVLIVDAFDI W.B. 3.65E-09 5.48E+04 2.00E-04 4.76E-10 4.20E+05 2.00E-04ADI-15941 VH1-2 ARVNHYDSSGYYGWFDP 2.87E-09 6.96E+04 2.00E-04 3.67E-09 5.45E+04 2.00E-04 N.B.ADI-15942 VH4-4 ATNRGLTFGELLFRDRGEAFDI 5.95E-09 3.36E+04 2.00E-04 4.43E-09 4.51E+04 2.00E-04 8.57E-10 2.33E+05 2.00E-04ADI-15943 VH4-34 ARHAHSGMDV 3.62E-09 1.44E+05 5.20E-04 N.B. N.B.ADI-15944 VH4-59 VRHYSDFWSGYHTPIWFDP W.B. 6.28E-09 5.70E+04 3.58E-04 3.35E-10 7.45E+05 2.50E-04ADI-15945 VH3-11 ARDSMVQGVFIHGPNDY W.B. 4.24E-09 4.72E+04 2.00E-04 5.54E-10 3.61E+05 2.00E-04ADI-15946 VH3-15 TTYTEDMRYFDWLLRGGETFDY 2.80E-09 7.13E+04 2.00E-04 3.24E-09 7.07E+04 2.29E-04 N.B.ADI-15947 VH4-34 ARGRSSTVVSRTTHFDY 2.09E-09 9.57E+04 2.00E-04 2.28E-09 8.78E+04 2.00E-04 N.B.ADI-15948 VH3-30 AREGFCSEGICTLGYQLDY W.B. N.B. 1.30E-09 2.81E+05 3.66E-04ADI-15949 VH3-11 ARGEGFRELLVKDYYGMDV W.B. 5.50E-09 5.37E+04 2.96E-04 6.38E-10 3.14E+05 2.00E-04ADI-15950 VH4-34 ARSRDYDFWTGHSRFFDY 9.95E-09 4.03E+04 4.01E-04 7.26E-09 8.89E+04 6.46E-04 3.39E-08 8.98E+04 3.04E-03ADI-15951 VH1-2 VVRYFDWNGPFDY 5.52E-09 3.62E+04 2.00E-04 3.38E-09 5.92E+04 2.00E-04 N.B.ADI-15952 VH4-34 TKVGSWNVGGMAFHI 3.98E-09 5.03E+04 2.00E-04 1.48E-08 5.25E+04 7.79E-04 N.B.ADI-15953 VH4-61 ARVQSPFNWNGYYSSLFFDY 2.45E-09 8.15E+04 2.00E-04 2.99E-09 6.69E+04 2.00E-04 N.B.ADI-15954 VH1-46 RRSGWSVTDYFDY 6.14E-09 3.42E+04 2.10E-04 3.99E-09 5.01E+04 2.00E-04 N.B.ADI-15955 VH3-21 ARDGALPADFVLLPAVNCFDP W.B. 4.55E-09 4.40E+04 2.00E-04 5.34E-10 3.74E+05 2.00E-04ADI-15956 VH1-46 ARDRYPTVVKYFGMDV 7.50E-10 2.67E+05 2.00E-04 8.25E-10 2.43E+05 2.00E-04 N.B.ADI-15957 VH3-23 ARSSELSGSYYLQAFDYFDY W.B. 1.73E-08 5.56E+04 9.60E-04 6.81E-10 2.94E+05 2.00E-04ADI-15958 VH4-34 ARVSLYFGYYMDV 6.04E-09 3.31E+04 2.00E-04 1.75E-08 3.94E+04 6.88E-04 N.B.ADI-15959 VH3-21 AREEITISGVLVHPVMDV 4.60E-09 4.35E+04 2.00E-04 9.93E-09 5.68E+04 5.64E-04 5.87E-10 3.41E+05 2.00E-04ADI-15960 VH3-48 ARGGYQDDLLVLVTPYDF 5.59E-09 3.58E+04 2.00E-04 4.42E-09 4.53E+04 2.00E-04 4.28E-10 4.68E+05 2.00E-04ADI-15961 VH1-3 ARGEIPLLVPPAMVRGFYYYMDV 7.69E-09 2.60E+04 2.00E-04 5.35E-09 3.74E+04 2.00E-04 8.34E-10 2.40E+05 2.00E-04ADI-15962 VH3-11 ARVAHGYDSYYFDH W.B. 1.03E-08 3.41E+04 3.50E-04 N.B.ADI-15963 VH4-34 ARGPIVVMVFVARPFDY 1.38E-09 3.41E+05 4.70E-04 5.15E-09 4.91E+05 2.53E-03 N.B.ADI-15964 VH3-7 AREAFLEWLAPLGHYYMDV 1.70E-09 1.17E+05 2.00E-04 2.17E-09 1.00E+05 2.17E-04 2.03E-09 3.33E+05 6.76E-04ADI-15965 VH3-48 ARVDSYYGILTGYPDY W.B. 9.17E-09 4.60E+04 4.22E-04 7.54E-10 2.65E+05 2.00E-04ADI-15966 VH1-2 VVRYFDWNGPIDY 5.18E-09 3.86E+04 2.00E-04 3.29E-09 6.08E+04 2.00E-04 N.B.ADI-15967 VH3-48 AREYFRSPGSLLRFSGNWFDP W.B. 1.57E-08 5.60E+04 8.78E-04 8.86E-10 2.86E+05 2.53E-04ADI-15968 VH2-5 AHSQTPVSRFLDWSQRLYFDY 1.15E-08 1.98E+04 2.28E-04 2.79E-08 3.86E+04 1.08E-03 5.12E-10 3.91E+05 2.00E-04ADI-15969 VH3-7 AREEDVNIAMGALGY 3.00E-08 5.91E+04 1.77E-03 4.93E-09 6.79E+04 3.35E-04 N.B.ADI-15970 VH3-23 AKDQDFWSGYSPPIT W.B. 2.64E-09 7.58E+04 2.00E-04 3.81E-10 5.49E+05 2.09E-04ADI-15971 VH3-33 ARESIRVGDTRSYFDY 3.86E-09 7.06E+04 2.72E-04 5.59E-09 8.53E+04 4.77E-04 N.B.ADI-15972 VH4-31 ARVPGARIGITFDI 7.67E-09 2.61E+04 2.00E-04 N.B. N.B.ADI-15973 VH4-30-4 ARLLWGSMRFLEWSPSGYFDS 4.46E-08 2.70E+04 1.20E-03 3.36E-08 5.37E+04 1.80E-03 1.86E-09 3.40E+05 6.32E-04ADI-15974 VH1-46 ARDRYPTVTKYFGMDV 9.51E-10 2.10E+05 2.00E-04 1.05E-09 1.90E+05 2.00E-04 N.B.ADI-15975 VH4-4 ARDRAVSINYYYYMDV 8.03E-10 2.67E+05 2.14E-04 1.52E-09 2.27E+05 3.44E-04 N.B.ADI-15976 VH4-59 ARLGRLITGTLWYSDY 8.89E-10 2.25E+05 2.00E-04 4.53E-09 1.87E+05 8.48E-04 N.B.ADI-15977 VH4-34 ARALPRGGNYRTFDY 2.06E-09 9.71E+04 2.00E-04 1.68E-09 1.19E+05 2.00E-04 N.B.ADI-15978 VH4-34 ARAWLRTSWYPSFDY 1.80E-09 1.11E+05 2.00E-04 1.91E-09 1.05E+05 2.00E-04 N.B.ADI-15979 VH3-64D VKGGGTTEYYYYGMDV 6.17E-09 3.24E+04 2.00E-04 N.B. N.B.ADI-15980 VH1-2 AREEGRNSLRYYYGMDV 3.05E-09 6.55E+04 2.00E-04 1.66E-08 3.49E+04 5.79E-04 N.B.ADI-15981 VH1-69 ARDLEWLGYCTGGVCYASSMDV W.B. 3.42E-08 5.22E+04 1.78E-03 N.B.ADI-15982 VH4-59 ARYYYDSRGYYSHYYHMDV 4.67E-09 4.28E+04 2.00E-04 9.19E-09 4.84E+04 4.45E-04 N.B.ADI-15983 VH1-2 ATPAPIVGATRGYYYHYYGMDV 9.88E-09 3.48E+04 3.44E-04 3.18E-09 6.29E+04 2.00E-04 N.B.ADI-15984 VH3-7 AREEDVNIAMGALGY 6.91E-09 5.64E+04 3.89E-04 2.64E-09 7.57E+04 2.00E-04 N.B.ADI-15985 VH4-34 ARGRVGPEILVPAAAGHYMDV 3.66E-09 5.46E+04 2.00E-04 3.86E-09 5.19E+04 2.00E-04 3.80E-10 5.26E+05 2.00E-04ADI-15986 VH3-23 AKDRDFWSGSRDFDY 8.53E-09 2.90E+04 2.47E-04 2.67E-09 7.49E+04 2.00E-04 3.15E-10 6.35E+05 2.00E-04ADI-15987 VH1-2 ARGPITNYVVINAYDYYMDV 5.57E-09 3.59E+04 2.00E-04 8.20E-09 4.44E+04 3.64E-04 6.85E-10 2.92E+05 2.00E-04ADI-15988 VH4-59 ARASITGFGVLIMEGVFDS 5.76E-09 3.48E+04 2.00E-04 4.09E-09 4.89E+04 2.00E-04 6.07E-10 3.29E+05 2.00E-04ADI-15989 VH1-2 ARGPGITMLLLAHRYEFDY 1.39E-08 4.26E+04 5.90E-04 2.58E-08 5.89E+04 1.52E-03 7.16E-10 3.58E+05 2.56E-04ADI-15990 VH4-59 ARGQRRDDYNLWLIRVNDAFDM 5.49E-09 3.65E+04 2.00E-04 4.59E-09 4.36E+04 2.00E-04 5.60E-10 3.57E+05 2.00E-04ADI-15991 VH1-18 ARHVWANQWLAENYYYYYMDV W.B. N.B. N.B.ADI-15992 VH3-64D VKDLEGSPYIQLWLLGY 9.01E-09 2.22E+04 2.00E-04 1.28E-08 3.15E+04 4.04E-04 7.44E-10 2.69E+05 2.00E-04ADI-15993 VH3-21 ARDHKEYISDWGVGYYYSGMDV W.B. N.B. 6.32E-10 3.16E+05 2.00E-04ADI-15994 VH3-48 ARVPYYGILTAGYFDY W.B. 1.86E-08 4.16E+04 7.76E-04 6.20E-10 3.23E+05 2.00E-04ADI-15995 VH1-46 ARETSKHDFWSGSPYHYYYMDV 7.89E-09 2.53E+04 2.00E-04 5.04E-09 3.97E+04 2.00E-04 N.B.ADI-15996 VH1-46 RRSGWSVTDYFDY 7.52E-09 2.66E+04 2.00E-04 4.75E-09 4.21E+04 2.00E-04 N.B.ADI-15997 VH1-24 ATVPPSTIFGVLIKGAQYNWFDP W.B. N.B. N.B.ADI-15998 VH3-21 ATQLVVGGYYYGMDV 1.34E-08 3.39E+04 4.53E-04 5.53E-09 4.33E+04 2.40E-04 N.B.ADI-15999 VH3-23 AKGRTSSA W.B. 1.97E-08 2.10E+05 4.15E-03 N.B.ADI-16000 VH4-34 ARGERFLEWSLANYYVDV W.B. N.B. 8.11E-10 2.47E+05 2.00E-04ADI-16001 VH3-15 TTDLWQPGSYYYYMDV W.B. 3.87E-09 5.17E+04 2.00E-04 N.B.ADI-16003 VH4-4 ARDGGGSNSSGFRVFRATFDY 4.08E-08 2.41E+05 9.82E-03 2.37E-08 3.32E+05 7.87E-03 N.B.ADI-16005 VH4-34 VRGPPGWYSSDWPIDY 3.57E-09 9.17E+04 3.27E-04 7.06E-09 8.53E+04 6.02E-04 N.B.ADI-16006 VH2-5 AHSLVAYSNSPVAFGSSWFLSSETTNYFDP 5.28E-09 3.79E+04 2.00E-04 3.99E-09 5.01E+04 2.00E-04 6.35E-10 4.46E+05 2.83E-04ADI-16007 VH1-18 ARCSELYYDILTSSYFFDY W.B. N.B. 1.21E-09 1.66E+05 2.00E-04ADI-16008 VH1-69 AREVGDMIGVILYTYYYMDV 6.23E-09 3.21E+04 2.00E-04 2.24E-09 8.92E+04 2.00E-04 6.04E-10 3.31E+05 2.00E-04ADI-16009 VH3-21 ARDLSFGGIIFINAFDL 7.07E-09 2.83E+04 2.00E-04 4.46E-09 4.49E+04 2.00E-04 3.95E-10 5.06E+05 2.00E-04ADI-16010 VH3-23 AAERLQWFDYLSSTDYYMDV W.B. 9.16E-09 4.02E+04 3.68E-04 9.16E-10 2.18E+05 2.00E-04ADI-16011 VH3-30 AKDSPGEQWLILSYYGMDV W.B. 3.50E-09 7.13E+04 2.50E-04 1.11E-09 1.79E+05 2.00E-04ADI-16012 VH1-3 GRDHVALLSAIFEPQYWIDP 5.36E-09 3.73E+04 2.00E-04 2.61E-09 7.68E+04 2.00E-04 6.11E-10 3.27E+05 2.00E-04ADI-16013 VH3-48 AKLGAPEQWLVSSKESYFDY W.B. 1.02E-08 4.81E+04 4.88E-04 2.43E-09 5.15E+05 1.25E-03ADI-16015 VH3-33 ARGGDIVVPAGSMDYYGMDV W.B. 1.45E-08 3.77E+04 5.46E-04 8.04E-10 2.49E+05 2.00E-04ADI-16016 VH3-48 ASGLRDLGVLLVPADYDGMDV W.B. 2.87E-08 3.53E+04 1.01E-03 6.90E-10 2.90E+05 2.00E-04




ADI-16017 VH4-39 ARHGYGDYLLTHYHFGLDV 6.05E-09 3.31E+04 2.00E-04 5.31E-09 3.77E+04 2.00E-04 5.32E-10 3.76E+05 2.00E-04ADI-16018 VH4-34 ARGPRRFGILIAHNWFDP 8.04E-09 2.49E+04 2.00E-04 7.81E-09 3.13E+04 2.45E-04 5.61E-10 3.57E+05 2.00E-04ADI-16019 VH4-59 ARDDYFGGVKI 6.98E-09 2.87E+04 2.00E-04 N.B. N.B.ADI-16020 VH1-2 ARGNFGRDLLLPAALGGWFDP 5.50E-09 3.64E+04 2.00E-04 6.85E-09 3.23E+04 2.21E-04 6.45E-10 3.10E+05 2.00E-04ADI-16021 VH3-33 ARGGSRGLEMATIYGGGLIY 1.21E-09 1.66E+05 2.00E-04 3.47E-09 3.15E+05 1.09E-03 N.B.ADI-16022 VH3-33 ARGWSYVDY 3.28E-08 1.10E+05 3.61E-03 1.13E-08 1.37E+05 1.55E-03 N.B.ADI-16024 VH1-2 ARGGVVDILTLTFYYAMDV 5.09E-09 3.93E+04 2.00E-04 2.81E-08 2.56E+04 7.20E-04 1.23E-09 4.22E+05 5.17E-04ADI-16025 VH4-39 ARADMLHEFIINRVAFDY 5.95E-09 3.36E+04 2.00E-04 5.03E-08 2.48E+04 1.25E-03 6.06E-09 3.78E+05 2.29E-03ADI-16026 VH4-34 ARGRGGDIVIPHDAVGGMDV 7.00E-09 2.86E+04 2.00E-04 N.B. 1.08E-09 2.52E+05 2.73E-04ADI-16027 VH1-18 ARSVLRYSDWLLYDADYMDV 6.00E-09 3.33E+04 2.00E-04 1.42E-08 3.01E+04 4.28E-04 6.75E-10 2.96E+05 2.00E-04ADI-16028 VH4-30-4 ARGPKSLAGIAMTGAFDY 5.75E-09 3.48E+04 2.00E-04 1.09E-08 3.21E+04 3.50E-04 7.59E-10 2.64E+05 2.00E-04ADI-16029 VH3-13 ARAVFGSSAFDI W.B. 2.53E-08 5.32E+04 1.35E-03 5.85E-09 1.71E+05 1.00E-03ADI-16030 VH1-2 ARAWPTDIVILPTALTGLDP 6.15E-09 3.25E+04 2.00E-04 9.08E-09 4.02E+04 3.65E-04 1.04E-09 2.26E+05 2.36E-04ADI-16031 VH4-34 ARALPRGGNYRTFDY 1.12E-09 1.78E+05 2.00E-04 1.15E-09 1.77E+05 2.04E-04 N.B.ADI-16032 VH3-11 ARGSYCTGVLCTHDAFDI 7.28E-09 2.94E+04 2.14E-04 1.28E-08 3.78E+04 4.85E-04 4.43E-10 5.00E+05 2.21E-04ADI-16033 VH3-23 TKEFQARLFELLVPASGVSYYGLDV W.B. N.B. 5.54E-09 2.47E+05 1.37E-03ADI-16034 VH4-4 ARLNSITLVRGVEGYYYMDV 1.32E-08 1.62E+04 2.14E-04 N.B. 7.80E-10 2.56E+05 2.00E-04ADI-16035 VH1-2 ARELSGDCSGGVCSGSGYFDY 5.06E-09 1.61E+05 8.15E-04 N.B. N.B.ADI-16036 VH3-23 AKDSEVFGVLILPRGMDV W.B. 2.04E-08 4.56E+04 9.30E-04 6.84E-09 4.44E+05 3.03E-03ADI-16037 VH3-21 ARDLGDILIVPAAFDY W.B. 5.23E-08 3.15E+04 1.65E-03 1.19E-09 2.66E+05 3.16E-04ADI-16038 VH4-30-4 ARGPKSLSGIAMAGAFDY 6.18E-09 3.24E+04 2.00E-04 4.44E-09 4.50E+04 2.00E-04 6.19E-10 3.23E+05 2.00E-04ADI-16039 VH1-2 ARSQYKWNYFPTPIDY 4.15E-09 4.82E+04 2.00E-04 5.00E-09 4.00E+04 2.00E-04 N.B.ADI-16040 VH4-34 ARGPMTTVTTWGIGYYDYGMDV 8.15E-09 2.45E+04 2.00E-04 N.B. 8.31E-10 2.41E+05 2.00E-04ADI-16041 VH4-59 ARHHPWGLHGGYGAYNLGWFVP 1.28E-08 3.81E+04 4.88E-04 9.20E-09 5.77E+04 5.31E-04 5.12E-09 5.10E+05 2.61E-03ADI-16042 VH3-21 ARGDDFVVVAGTIDYSHYVMDV W.B. N.B. 6.54E-10 3.06E+05 2.00E-04ADI-16043 VH3-23 ARLQRFSFTMGVVVITEPAFDL W.B. N.B. 3.09E-09 6.47E+04 2.00E-04ADI-16044 VH1-69 ARLVWDIVILPGSTAYYYMDV 6.32E-09 3.17E+04 2.00E-04 6.16E-09 4.33E+04 2.67E-04 6.72E-10 2.98E+05 2.00E-04ADI-16045 VH3-30 ATRRFRELLERYDYYGLDV W.B. N.B. 1.34E-09 1.99E+05 2.67E-04ADI-16046 VH3-15 VTPPVGPHQYYVY W.B. 3.23E-09 6.78E+04 2.19E-04 6.45E-10 3.10E+05 2.00E-04ADI-16047 VH2-5 AHVNVITVFGVIIVPSGWFDP 4.21E-09 4.75E+04 2.00E-04 6.80E-09 5.06E+04 3.44E-04 N.B.ADI-16048 VH4-39 ARLKSTDNDFWNGYPDY W.B. N.B. 4.84E-09 1.34E+05 6.48E-04ADI-16049 VH4-39 ARADMLQGIIITRVAFDY 5.90E-09 3.39E+04 2.00E-04 6.55E-09 3.05E+04 2.00E-04 4.70E-10 4.26E+05 2.00E-04ADI-16050 VH4-34 ARGETVRLDP 7.50E-09 2.90E+04 2.18E-04 4.79E-09 4.18E+04 2.00E-04 N.B.ADI-16051 VH5-10-1 ARHTYNSDWGTANIAMDV W.B. N.B. 1.32E-09 1.51E+05 2.00E-04ADI-16052 VH3-49 IRDVST W.B. 5.10E-09 3.93E+04 2.00E-04 N.B.ADI-16053 VH3-48 AREGPTPMDYYYYYMDV 1.85E-08 4.25E+04 7.88E-04 3.19E-09 7.86E+04 2.51E-04 N.B.ADI-16054 VH1-2 ARGPAADCTGGVCFFLERSDAFDI 6.46E-09 3.10E+04 2.00E-04 1.65E-08 4.69E+04 7.72E-04 1.71E-09 3.50E+05 5.99E-04ADI-16055 VH3-48 ARGNGDERAVYYYYGMDV W.B. 9.13E-09 3.20E+04 2.92E-04 5.71E-10 3.51E+05 2.00E-04ADI-16056 VH3-21 ARDVTDSSGYLYLNAFDL W.B. N.B. 9.84E-10 2.03E+05 2.00E-04ADI-16058 VH1-3 ARGLEDTVVVQELNWFDP 7.45E-09 2.68E+04 2.00E-04 1.73E-08 4.37E+04 7.56E-04 5.93E-10 3.37E+05 2.00E-04ADI-16059 VH3-23 AKEKDFWNGYYIDY W.B. 3.47E-09 5.76E+04 2.00E-04 4.79E-10 4.18E+05 2.00E-04ADI-16060 VH4-59 AGDQGFCTNGVCFRVGWFDP 7.26E-09 2.76E+04 2.00E-04 N.B. 9.79E-10 2.04E+05 2.00E-04ADI-16061 VH1-46 ARDRYPVLFATDYGMDV 8.35E-10 2.39E+05 2.00E-04 8.76E-10 2.28E+05 2.00E-04 N.B.ADI-16062 VH4-34 ARALRTIWDGYYNYMDV 1.50E-08 6.52E+05 9.75E-03 P.F. N.B.ADI-16063 VH4-34 ARGTYKDIGVLIAATYYDH 6.24E-09 3.20E+04 2.00E-04 N.B. 9.03E-10 2.22E+05 2.00E-04

† 2.0E-04 is the upper limit of Koff in this assay

* N.B., non-binder; W.B., weak binder. IgG KDs were calculated for MAbs with ForteBio binding responses >0.1 nm. MAbs with ForteBio binding responses <0.05 nm were designated as N.B.; MAbs with ForteBio binding responses between 0.05 and 0.1 nm were designated as W.B.

Table S4. Competition of ADI-15972, ADI-15983, ADI-15910, and ADI-15933 with each other and with control mAbs.

KZ52 ADI-15974 ADI-15810 ADI-15983 ADI-15933KZ52 96.3 1.0 0.9 0.8 1.2

ADI-15974 1.2 42.3 0.9 0.9 0.9ADI-15810 4.7 2.4 59.9 1.7 1.0ADI-15983 1.0 0.9 0.8 32.4 0.9ADI-15933 1.2 0.9 0.8 0.8 25.8

ResultsareexpressedasthefoldreductioninantigenbindinginthepresenceofsaturatingconcentrationsofcompetitorFabrelativetoanantigen-onlycontrol.

Table S5. Neutralization screening. Clone name IgG concentration tested in

preliminary screen (µg/ml)PRNT50 reached in preliminary screen?

PRNT80 reached in preliminary screen?

PRNT50 (µg/ml) PRNT80 (µg/ml) IgG KD GP∆TM (M)*

IgG KD GP∆Muc (M)*

IgG KD sGP (M)*

Competition group

13C6 IgG N.D. N.D. N.D. >5.0 >5.0 8.02E-09 2.20E-08 N.D. 13C6/1H31H3 IgG N.D. N.D. N.D. 1.40E-08 4.56E-09 N.D. 13C6/1H3

ADI-15731 38.6 + + 0.6 1.21 5.0E-09 7.4E-09 4.5E-10 13C6/1H3ADI-15733 80.1 + + 5.01 20.03 W.B. W.B. 1.1E-09 13C6/1H3ADI-15735 71.7 + + 4.48 17.92 W.B. 4.4E-08 6.0E-10 13C6/1H3ADI-15736 27.0 + + 1.69 6.74 W.B. 7.0E-08 7.9E-10 13C6/1H3ADI-15737 6.7 + + 1.68 1.5E-08 3.6E-08 6.4E-10 13C6/1H3ADI-15738 58.3 + + 7.29 W.B. W.B. 1.0E-09 13C6/1H3ADI-15739 58.7 + + 3.67 W.B. N.B. 3.1E-09 13C6/1H3ADI-15740 37.9 + + 9.48 W.B. 3.3E-08 1.5E-09 13C6/1H3ADI-15744 102.7 + + 0.8 1.6 1.5E-08 3.3E-08 5.2E-10 13C6/1H3ADI-15746 13.7 + + W.B. N.B. 1.7E-09 13C6/1H3ADI-15747 24.5 + + W.B. W.B. 1.5E-09 13C6/1H3ADI-15749 22.7 + + 1.4E-08 1.4E-08 7.5E-10 13C6/1H3ADI-15750 32.1 + + 4.01 W.B. 4.2E-09 9.3E-10 13C6/1H3ADI-15752 42.0 + + 5.6E-09 1.4E-08 5.6E-10 13C6/1H3ADI-15754 115.8 + + 28.95 7.2E-09 4.7E-09 5.6E-10 13C6/1H3ADI-15755 74.6 + + 18.66 7.6E-09 3.3E-09 7.9E-10 13C6/1H3ADI-15756 49.4 + + 1.54 3.09 7.6E-09 4.8E-09 7.5E-10 13C6/1H3ADI-15760 75.3 + + 1.18 2.35 5.3E-09 1.1E-08 9.8E-10 13C6/1H3ADI-15761 18.1 + + 4.54 5.4E-09 4.9E-09 8.4E-10 13C6/1H3ADI-15763 112.4 + + 3.51 6.2E-09 8.7E-09 8.8E-10 13C6/1H3ADI-15764 97.6 + + 0.76 1.53 4.2E-09 3.8E-09 3.9E-10 13C6/1H3ADI-15766 109.9 + + 3.43 6.87 6.3E-09 1.4E-08 7.3E-10 13C6/1H3ADI-15767 69.8 + + 4.36 4.36 W.B. 6.5E-09 1.3E-09 13C6/1H3ADI-15768 72.7 + + 2.27 4.55 W.B. 5.6E-09 6.3E-10 13C6/1H3ADI-15769 52.9 + + 3.31 6.61 W.B. W.B. 1.1E-09 13C6/1H3ADI-15771 25.8 - - W.B. 6.5E-09 1.0E-09 13C6/1H3ADI-15773 23.1 + + 2.89 5.77 5.9E-09 3.8E-09 7.7E-10 13C6/1H3ADI-15774 33.2 + + W.B. W.B. 4.0E-09 13C6/1H3ADI-15775 5.7 + + 5.1E-09 4.9E-09 1.6E-09 13C6/1H3ADI-15787 45.8 + + 5.2E-09 3.7E-09 3.7E-10 13C6/1H3ADI-15788 14.4 + + 4.7E-09 4.3E-09 5.3E-10 13C6/1H3ADI-15789 72.4 + + 4.52 18.09 W.B. 4.8E-09 7.6E-10 13C6/1H3ADI-15791 37.1 + + 2.32 9.27 W.B. 3.8E-09 5.4E-10 13C6/1H3ADI-15792 33.7 + + 2.1 8.41 7.3E-09 1.2E-08 6.2E-10 13C6/1H3ADI-15793 20.3 + + 5.07 5.9E-09 1.6E-08 6.1E-10 13C6/1H3ADI-15794 85.5 + + 5.35 21.38 W.B. W.B. 1.3E-09 13C6/1H3ADI-15795 117.0 + + 7.31 29.25 W.B. 3.0E-09 6.1E-10 13C6/1H3ADI-15796 14.3 + + 0.89 W.B. 4.0E-09 5.1E-10 13C6/1H3ADI-15797 6.7 + + 7.3E-09 3.0E-09 6.0E-10 13C6/1H3ADI-15799 12.1 + + W.B. 4.3E-09 5.7E-10 13C6/1H3ADI-15800 22.7 + + W.B. 4.0E-09 3.4E-09 13C6/1H3ADI-15801 14.7 + + W.B. W.B. 1.1E-09 13C6/1H3ADI-15802 1.6 - - 3.8E-09 2.7E-09 5.2E-10 13C6/1H3ADI-15803 6.9 + + W.B. 3.3E-09 6.7E-10 13C6/1H3ADI-15806 22.0 + + 5.9E-09 4.4E-09 6.8E-10 13C6/1H3ADI-15807 14.2 - - 6.1E-09 1.6E-08 1.1E-09 13C6/1H3ADI-15809 118.5 + + <0.93 <0.93 5.5E-09 3.7E-09 4.8E-10 13C6/1H3ADI-15814 102.3 - - W.B. 1.6E-08 1.0E-08 13C6/1H3ADI-15815 23.2 + - W.B. W.B. 1.1E-09 13C6/1H3ADI-15817 117.3 + + 0.46 3.67 6.5E-09 5.1E-09 6.2E-10 13C6/1H3ADI-15821 14.3 + + W.B. 1.2E-08 5.5E-10 13C6/1H3ADI-15823 16.7 + + W.B. 3.8E-09 3.8E-10 13C6/1H3ADI-15824 24.8 + + W.B. 1.9E-09 3.5E-10 13C6/1H3ADI-15825 13.1 + + W.B. 4.9E-09 5.0E-10 13C6/1H3ADI-15826 37.8 + + 2.7E-08 2.1E-08 7.2E-10 13C6/1H3ADI-15827 32.3 + + W.B. 1.4E-08 5.6E-10 13C6/1H3ADI-15828 14.9 + + W.B. W.B. 8.0E-10 13C6/1H3ADI-15829 21.0 + + 7.2E-09 7.0E-09 5.7E-10 13C6/1H3ADI-15830 26.9 + + 9.2E-09 3.4E-09 3.2E-10 13C6/1H3ADI-15831 14.3 + - W.B. 4.0E-09 5.1E-10 13C6/1H3ADI-15832 27.9 + + W.B. 2.4E-08 8.2E-10 13C6/1H3ADI-15833 25.9 - - W.B. 1.1E-08 2.5E-09 13C6/1H3ADI-15834 29.9 + + 5.0E-09 3.4E-09 5.0E-10 13C6/1H3ADI-15835 34.4 + - W.B. W.B. 9.4E-10 13C6/1H3ADI-15837 35.2 + + W.B. 2.9E-09 3.2E-10 13C6/1H3ADI-15840 22.1 + + W.B. 8.6E-09 6.4E-10 13C6/1H3ADI-15849 2.2 + + W.B. 1.7E-09 W.B. 13C6/1H3ADI-15853 21.5 + + 1.4E-08 2.0E-08 5.4E-10 13C6/1H3ADI-15856 18.4 + + 4.7E-09 8.8E-09 3.1E-10 13C6/1H3ADI-15862 6.6 + + 1.1E-08 4.1E-09 5.5E-10 13C6/1H3ADI-15863 17.3 + + 7.4E-09 3.2E-09 3.8E-10 13C6/1H3ADI-15864 17.7 + + W.B. 2.7E-08 7.8E-10 13C6/1H3ADI-15866 20.1 + + W.B. W.B. 7.8E-10 13C6/1H3ADI-15867 11.5 + + 7.1E-09 4.0E-09 6.5E-10 13C6/1H3ADI-15869 11.8 + + 7.2E-09 4.4E-09 5.5E-10 13C6/1H3ADI-15870 8.9 + + 7.3E-09 3.3E-09 3.3E-10 13C6/1H3ADI-15872 18.1 - - 5.5E-09 4.1E-09 3.2E-10 13C6/1H3ADI-15874 36.6 + + 4.9E-09 6.8E-09 3.2E-10 13C6/1H3ADI-15875 16.2 + + 7.3E-09 4.6E-09 7.6E-10 13C6/1H3ADI-15880 1.0 - - W.B. W.B. 2.8E-09 13C6/1H3ADI-15885 17.0 + + W.B. 1.4E-08 7.8E-10 13C6/1H3ADI-15888 19.8 + + 6.7E-09 8.5E-09 4.0E-10 13C6/1H3ADI-15889 29.7 + + 5.5E-09 4.5E-09 4.4E-10 13C6/1H3ADI-15890 38.6 + - 6.8E-09 2.2E-08 5.8E-10 13C6/1H3ADI-15891 30.9 + + 4.6E-09 3.4E-09 3.5E-10 13C6/1H3ADI-15892 48.3 + + W.B. 3.9E-09 5.8E-10 13C6/1H3ADI-15894 14.6 + + 2.7E-08 8.0E-09 6.2E-10 13C6/1H3ADI-15896 21.4 + + W.B. 7.5E-09 5.6E-10 13C6/1H3ADI-15897 13.0 + - 1.5E-08 3.5E-09 2.8E-10 13C6/1H3ADI-15898 15.4 + + W.B. 3.7E-09 4.1E-10 13C6/1H3ADI-15899 13.3 + - W.B. 5.4E-09 6.3E-10 13C6/1H3ADI-15900 10.0 + - W.B. W.B. 1.3E-09 13C6/1H3ADI-15902 19.7 + + W.B. 4.5E-09 3.2E-09 13C6/1H3ADI-15904 31.0 + + W.B. 1.5E-08 5.0E-10 13C6/1H3

Table S5 (continued). Neutralization screening. Clone name IgG concentration tested in





IgG KD sGP (M)*

Competition group

ADI-15906 20.7 + - W.B. W.B. 9.7E-10 13C6/1H3ADI-15907 17.6 + + W.B. 4.4E-09 5.0E-10 13C6/1H3ADI-15910 20.2 + - W.B. 6.3E-09 1.3E-09 13C6/1H3ADI-15913 27.2 + + W.B. 1.6E-08 3.0E-09 13C6/1H3ADI-15914 27.4 + + 6.2E-09 4.5E-09 4.0E-10 13C6/1H3ADI-15917 19.6 + + 6.7E-09 7.2E-09 5.4E-10 13C6/1H3ADI-15918 49.7 + + 6.3E-09 3.9E-09 4.4E-10 13C6/1H3ADI-15919 30.8 + + W.B. 1.4E-08 5.0E-10 13C6/1H3ADI-15920 29.8 + + W.B. 3.7E-09 3.4E-10 13C6/1H3ADI-15921 49.9 - - 6.7E-09 2.2E-08 1.6E-09 13C6/1H3ADI-15922 25.7 + + W.B. 2.7E-08 6.0E-10 13C6/1H3ADI-15923 26.3 + + 4.7E-09 9.7E-09 5.3E-10 13C6/1H3ADI-15924 3.9 + - W.B. 6.6E-09 1.0E-09 13C6/1H3ADI-15926 76.8 + + 2.4 4.8 4.9E-09 2.6E-08 6.8E-10 13C6/1H3ADI-15927 69.1 + + 4.32 4.32 5.2E-09 W.B. 9.8E-10 13C6/1H3ADI-15928 18.7 N.D. N.D. 2.33 4.67 5.2E-09 3.8E-08 6.4E-10 13C6/1H3ADI-15929 3.3 + + W.B. W.B. 8.8E-10 13C6/1H3ADI-15930 115.6 + + 3.61 6.8E-09 4.7E-08 6.8E-10 13C6/1H3ADI-15931 10.8 + - W.B. W.B. 1.1E-09 13C6/1H3ADI-15932 10.2 + + 0.625 2.5 5.1E-09 2.0E-08 5.3E-10 13C6/1H3ADI-15934 4.9 + - W.B. 1.5E-08 1.3E-09 13C6/1H3ADI-15936 48.6 N.D. N.D. 1.52 6.07 W.B. W.B. 7.5E-10 13C6/1H3ADI-15937 28.4 + + 7.1 6.8E-09 W.B. 7.0E-10 13C6/1H3ADI-15938 51.5 + + 1.61 1.61 7.1E-09 W.B. 8.2E-10 13C6/1H3ADI-15939 79.6 + + 4.97 9.95 W.B. W.B. 1.1E-09 13C6/1H3ADI-15940 5.1 + + 0.63 1.27 W.B. 3.7E-09 4.8E-10 13C6/1H3ADI-15942 12.5 + + 6.0E-09 4.4E-09 8.6E-10 13C6/1H3ADI-15945 21.2 + + W.B. 4.2E-09 5.5E-10 13C6/1H3ADI-15948 0.9 - - W.B. W.B. 1.3E-09 13C6/1H3ADI-15949 6.3 + - W.B. 5.5E-09 6.4E-10 13C6/1H3ADI-15950 52.5 - - 9.9E-09 7.3E-09 3.4E-08 13C6/1H3ADI-15955 20.3 + + W.B. 4.5E-09 5.3E-10 13C6/1H3ADI-15957 27.8 + + W.B. 1.7E-08 6.8E-10 13C6/1H3ADI-15961 13.5 + + 7.7E-09 5.4E-09 8.3E-10 13C6/1H3ADI-15962 29.7 + + W.B. 1.0E-08 W.B 13C6/1H3ADI-15964 2.7 + + 1.7E-09 2.2E-09 2.0E-09 13C6/1H3ADI-15965 18.4 + - W.B. 9.2E-09 7.5E-10 13C6/1H3ADI-15967 8.0 - - W.B. 1.6E-08 8.9E-10 13C6/1H3ADI-15968 28.5 + + 1.2E-08 2.8E-08 5.1E-10 13C6/1H3ADI-15973 10.4 + - 4.5E-08 3.4E-08 1.9E-09 13C6/1H3ADI-15985 29.7 - - 3.7E-09 3.9E-09 3.8E-10 13C6/1H3ADI-15987 29.8 + + 5.6E-09 8.2E-09 6.8E-10 13C6/1H3ADI-15988 38.7 + + 5.8E-09 4.1E-09 6.1E-10 13C6/1H3ADI-15989 46.2 + - 1.4E-08 2.6E-08 7.2E-10 13C6/1H3ADI-15990 22.9 + + 5.5E-09 4.6E-09 5.6E-10 13C6/1H3ADI-15992 118.2 + + 14.78 29.56 9.0E-09 1.3E-08 7.4E-10 13C6/1H3ADI-15993 13.4 + + W.B. W.B. 6.3E-10 13C6/1H3ADI-15994 5.4 + - W.B. 1.9E-08 6.2E-10 13C6/1H3ADI-16000 2.6 + + W.B. W.B. 8.1E-10 13C6/1H3ADI-16006 3.0 + + 5.3E-09 4.0E-09 6.4E-10 13C6/1H3ADI-16007 21.7 + + W.B. W.B. 1.2E-09 13C6/1H3ADI-16008 48.5 + + 6.2E-09 2.2E-09 6.0E-10 13C6/1H3ADI-16009 12.7 + + 7.1E-09 4.5E-09 4.0E-10 13C6/1H3ADI-16010 28.1 + + W.B. 9.2E-09 9.2E-10 13C6/1H3ADI-16011 16.5 + + W.B. 3.5E-09 1.1E-09 13C6/1H3ADI-16012 28.3 + + 5.4E-09 2.6E-09 6.1E-10 13C6/1H3ADI-16013 28.6 + + W.B. 1.0E-08 2.4E-09 13C6/1H3ADI-16015 14.3 + + W.B. 1.4E-08 8.0E-10 13C6/1H3ADI-16016 15.8 + + W.B. 2.9E-08 6.9E-10 13C6/1H3ADI-16017 20.4 + - 6.0E-09 5.3E-09 5.3E-10 13C6/1H3ADI-16018 12.7 + + 8.0E-09 7.8E-09 5.6E-10 13C6/1H3ADI-16020 35.8 + + 5.5E-09 6.8E-09 6.4E-10 13C6/1H3ADI-16024 10.6 - - 5.1E-09 2.8E-08 1.2E-09 13C6/1H3ADI-16025 80.7 - - 6.0E-09 5.0E-08 6.1E-09 13C6/1H3ADI-16026 117.6 + + 3.68 7.35 7.0E-09 W.B. 1.1E-09 13C6/1H3ADI-16027 48.9 + + 6.0E-09 1.4E-08 6.7E-10 13C6/1H3ADI-16028 24.0 + - 5.7E-09 1.1E-08 7.6E-10 13C6/1H3ADI-16029 124.8 + + 31.19 31.19 W.B. 2.5E-08 5.9E-09 13C6/1H3ADI-16030 29.1 + + 6.1E-09 9.1E-09 1.0E-09 13C6/1H3ADI-16032 37.5 + + 7.3E-09 1.3E-08 4.4E-10 13C6/1H3ADI-16033 85.4 - - W.B. W.B. 5.5E-09 13C6/1H3ADI-16034 28.8 + + 1.3E-08 W.B. 7.8E-10 13C6/1H3ADI-16036 120.2 - - W.B. 2.0E-08 6.8E-09 13C6/1H3ADI-16037 27.1 + + 0.85 1.69 W.B. 5.2E-08 1.2E-09 13C6/1H3ADI-16038 57.3 + + 7.16 14.33 6.2E-09 4.4E-09 6.2E-10 13C6/1H3ADI-16040 53.4 + + 1.67 3.33 8.2E-09 W.B. 8.3E-10 13C6/1H3ADI-16044 112.7 + + <0.11 1.76 6.3E-09 6.2E-09 6.7E-10 13C6/1H3ADI-16045 91.2 + + 5.7 W.B. W.B. 1.3E-09 13C6/1H3ADI-16046 93.4 + + 1.46 2.92 W.B. 3.2E-09 6.5E-10 13C6/1H3ADI-16048 115.6 + + 3.61 7.22 W.B. W.B. 4.8E-09 13C6/1H3ADI-16049 100.1 + + 1.56 5.9E-09 6.6E-09 4.7E-10 13C6/1H3ADI-16051 39.4 + + W.B. W.B. 1.3E-09 13C6/1H3ADI-16054 39.6 + - 6.5E-09 1.6E-08 1.7E-09 13C6/1H3ADI-16055 46.7 + + W.B. 9.1E-09 5.7E-10 13C6/1H3ADI-16056 26.2 + + W.B. W.B. 9.8E-10 13C6/1H3ADI-16058 13.6 + + 7.5E-09 1.7E-08 5.9E-10 13C6/1H3ADI-16060 10.0 + + 7.3E-09 W.B. 9.8E-10 13C6/1H3ADI-16063 16.0 + + 6.2E-09 W.B. 9.0E-10 13C6/1H3ADI-15748 45.3 + - 9.4E-09 3.6E-09 N.B. ADI-15810ADI-15753 24.5 - - 5.2E-09 3.1E-09 N.B. ADI-15810ADI-15777 71.2 - - 8.8E-09 3.5E-09 N.B. ADI-15810ADI-15779 99.9 - - 6.7E-09 3.1E-09 N.B. ADI-15810ADI-15781 17.1 - - 4.2E-08 2.8E-08 N.B. ADI-15810ADI-15804 10.7 - - 5.6E-09 3.2E-09 N.B. ADI-15810ADI-15810 117.8 - - 7.6E-09 3.8E-09 N.B. ADI-15810ADI-15812 66.4 - - 1.4E-08 3.7E-09 N.B. ADI-15810






IgG KD sGP (M)*

Competition group

ADI-15813 110.1 - - W.B. 2.6E-08 N.B. ADI-15810ADI-15858 23.6 + + W.B. 4.1E-09 N.B. ADI-15810ADI-15859 70.3 + + 2.2 17.58 1.4E-08 3.4E-09 N.B. ADI-15810ADI-15882 44.3 + + 1.38 >20 8.1E-09 3.7E-09 N.B. ADI-15810ADI-15884 36.9 + - 1.4E-08 3.1E-09 N.B. ADI-15810ADI-15893 44.4 N.D. N.D. 2.5E-08 1.4E-08 N.B. ADI-15810ADI-15895 28.6 + - W.B. 2.9E-09 N.B. ADI-15810ADI-15951 96.9 + + 6.06 24.23 5.5E-09 3.4E-09 N.B. ADI-15810ADI-15954 36.9 - - 6.1E-09 4.0E-09 N.B. ADI-15810ADI-15966 112.4 - - 5.2E-09 3.3E-09 N.B. ADI-15810ADI-15969 27.1 - - 3.0E-08 4.9E-09 N.B. ADI-15810ADI-15984 79.6 - - 6.9E-09 2.6E-09 N.B. ADI-15810ADI-15996 19.8 - - 7.5E-09 4.7E-09 N.B. ADI-15810ADI-15998 19.6 + - 1.3E-08 5.5E-09 N.B. ADI-15810ADI-16001 38.5 + - W.B. 3.9E-09 N.B. ADI-15810ADI-16050 91.6 - - 7.5E-09 4.8E-09 N.B. ADI-15810ADI-16053 29.9 - - 1.9E-08 3.2E-09 N.B. ADI-15810ADI-15933 100.7 + + 12.58 3.2E-09 2.9E-09 N.B. ADI-15933ADI-16022 64.5 - - 3.3E-08 1.1E-08 N.B. ADI-15933ADI-15732 30.4 + - 7.6 3.2E-09 2.0E-09 N.B. ADI-15974ADI-15745 49.3 + - 9.7E-08 4.4E-08 N.B. ADI-15974ADI-15757 52.4 + + 3.27 13.09 2.0E-09 2.9E-09 N.B. ADI-15974ADI-15758 15.5 + + 0.03 0.12 7.8E-10 8.7E-10 N.B. ADI-15974ADI-15782 106.1 - - 6.7E-10 1.3E-09 N.B. ADI-15974ADI-15785 13.7 + + 0.85 1.71 2.3E-09 1.6E-09 N.B. ADI-15974ADI-15805 11.4 - - 1.5E-08 1.6E-08 N.B. ADI-15974ADI-15811 123.8 - - 8.0E-08 2.0E-08 N.B. ADI-15974ADI-15819 100.3 - - 1.2E-08 4.8E-09 N.B. ADI-15974ADI-15820 102.9 + + <0.08 <0.08 7.7E-10 2.4E-09 N.B. ADI-15974ADI-15841 14.1 + - 9.6E-10 7.7E-10 N.B. ADI-15974ADI-15844 121.2 - - 9.8E-09 1.3E-08 N.B. ADI-15974ADI-15845 16.1 - - 1.5E-09 2.0E-09 N.B. ADI-15974ADI-15848 31.6 + + ≤0.03 ≤0.03 6.0E-10 5.2E-10 N.B. ADI-15974ADI-15852 1.2 - - 1.4E-08 2.4E-09 N.B. ADI-15974ADI-15886 71.4 + + 8.92 >20 W.B. 4.1E-09 N.B. ADI-15974ADI-15901 56.9 - - 8.0E-10 2.9E-09 N.B. ADI-15974ADI-15916 18.9 + - 9.1E-10 6.5E-10 N.B. ADI-15974ADI-15925 31.7 - - 9.8E-10 8.8E-10 N.B. ADI-15974ADI-15941 77.2 + - 19.31 2.9E-09 3.7E-09 N.B. ADI-15974ADI-15956 36.4 + + ≤0.04 0.07 7.5E-10 8.2E-10 N.B. ADI-15974ADI-15963 75.8 - - 1.4E-09 5.2E-09 N.B. ADI-15974ADI-15974 48.4 + + ≤0.05 0.09 9.5E-10 1.1E-09 N.B. ADI-15974ADI-15975 11.5 N.D. N.D. 8.0E-10 1.5E-09 N.B. ADI-15974ADI-15976 28.6 + - 8.9E-10 4.5E-09 N.B. ADI-15974ADI-15981 46.5 + - W.B. 3.4E-08 N.B. ADI-15974ADI-15999 44.1 + + ≤0.04 0.17 W.B. 2.0E-08 N.B. ADI-15974ADI-16003 68.6 - - 4.1E-08 2.4E-08 N.B. ADI-15974ADI-16021 0.9 - - 1.2E-09 3.5E-09 N.B. ADI-15974ADI-16061 19.3 + + ≤0.02 0.08 8.4E-10 8.8E-10 N.B. ADI-15974ADI-16062 75.2 - - 1.5E-08 P.F. N.B. ADI-15974ADI-15855 125.9 - - W.B. 1.9E-09 N.B. ADI-15983ADI-15972 20.3 - - 7.7E-09 W.B. N.B. ADI-15983ADI-15983 46.4 N.D. N.D. 9.9E-09 3.2E-09 N.B. ADI-15983ADI-16052 26.1 - - W.B. 5.1E-09 N.B. ADI-159832G4 IgG N.D. N.D. N.D. 1.29E-08 1.13E-08 KZ52

ADI-15734 36.3 + + 0.14 0.28 1.9E-09 5.8E-09 N.B. KZ52 ADI-15741 53.8 - - 1.5E-09 1.6E-09 N.B. KZ52 ADI-15742 47.3 + + 0.37 0.74 W.B. 4.8E-09 N.B. KZ52 ADI-15743 114.0 - - 1.0E-09 1.2E-09 N.B. KZ52 ADI-15759 112.7 + + 14.09 28.19 6.3E-09 5.6E-09 N.B. KZ52 ADI-15762 27.1 + + 0.85 6.78 2.6E-08 6.4E-09 N.B. KZ52 ADI-15772 80.3 + + 0.31 0.63 4.5E-09 3.0E-09 N.B. KZ52 ADI-15780 30.1 + + 1.88 4.0E-09 3.1E-09 N.B. KZ52 ADI-15783 50.3 + + 12.58 2.0E-09 2.2E-09 N.B. KZ52 ADI-15784 113.6 + + 0.22 0.44 5.4E-09 2.5E-09 N.B. KZ52 ADI-15786 79.9 - - 6.2E-09 6.6E-09 N.B. KZ52 ADI-15798 6.4 + + W.B. 7.5E-09 N.B. KZ52 ADI-15818 81.8 + + ≤0.16 0.08 W.B. 2.3E-09 N.B. KZ52 ADI-15822 126.4 - - 9.9E-09 2.0E-08 N.B. KZ52 ADI-15839 24.4 - - 1.2E-09 9.9E-10 N.B. KZ52 ADI-15842 28.0 - - 1.5E-09 1.8E-09 N.B. KZ52 ADI-15843 18.6 + - 2.3E-09 2.0E-09 N.B. KZ52 ADI-15847 31.1 + + W.B. 1.4E-09 N.B. KZ52 ADI-15850 27.5 + + W.B. 2.5E-09 N.B. KZ52 ADI-15851 16.6 + - 3.3E-09 7.8E-09 N.B. KZ52 ADI-15854 29.4 + - W.B. 4.2E-09 N.B. KZ52 ADI-15860 24.2 N.D. N.D. 2.3E-09 1.4E-08 N.B. KZ52 ADI-15861 33.7 + - 3.0E-09 2.3E-09 N.B. KZ52 ADI-15865 31.9 + - 1.5E-09 1.5E-09 N.B. KZ52 ADI-15868 24.4 - - W.B. 3.9E-09 N.B. KZ52 ADI-15871 72.8 + + 1.14 2.28 4.5E-09 3.8E-09 N.B. KZ52 ADI-15873 115.2 - - 4.6E-09 8.5E-09 N.B. KZ52 ADI-15876 25.4 - - W.B. 4.4E-09 N.B. KZ52 ADI-15877 34.3 - - 3.3E-09 2.3E-09 N.B. KZ52 ADI-15878 54.6 + + ≤0.05 0.11 W.B. 1.7E-09 N.B. KZ52 ADI-15879 126.1 + + ≤0.12 7.88 W.B. 3.4E-09 N.B. KZ52 ADI-15881 84.4 + + ≤0.08 21.1 W.B. W.B. N.B. KZ52 ADI-15883 123.5 + + 0.97 3.86 W.B. 4.1E-09 N.B. KZ52 ADI-15887 4.9 + + 6.2E-09 3.4E-09 N.B. KZ52 ADI-15908 82.6 + + 20.66 >20 1.6E-09 1.3E-09 N.B. KZ52 ADI-15909 122.3 - - 1.1E-09 1.2E-09 N.B. KZ52 ADI-15911 1.0 - - W.B. 1.6E-09 N.B. KZ52 ADI-15912 13.5 + - 1.3E-09 1.2E-09 N.B. KZ52 ADI-15915 40.3 + - W.B. 5.0E-09 N.B. KZ52 ADI-15935 56.1 + + 0.03 0.07 1.1E-09 1.6E-09 N.B. KZ52 ADI-15946 40.7 + + 2.8E-09 3.2E-09 N.B. KZ52






IgG KD sGP (M)*

Competition group

ADI-15947 7.0 + - 2.1E-09 2.3E-09 N.B. KZ52 ADI-15952 0.9 + - 4.0E-09 1.5E-08 N.B. KZ52 ADI-15953 16.0 + + 2.5E-09 3.0E-09 N.B. KZ52 ADI-15958 4.7 - - 6.0E-09 1.7E-08 N.B. KZ52 ADI-15977 21.0 - - 2.1E-09 1.7E-09 N.B. KZ52 ADI-15978 12.5 + + 1.8E-09 1.9E-09 N.B. KZ52 ADI-15982 4.5 - - 4.7E-09 9.2E-09 N.B. KZ52 ADI-15991 13.6 + - W.B. W.B. N.B. KZ52 ADI-15995 39.8 + + 2.49 4.98 7.9E-09 5.0E-09 N.B. KZ52 ADI-15997 12.8 + - W.B. W.B. N.B. KZ52 ADI-16005 12.8 + + 3.6E-09 7.1E-09 N.B. KZ52 ADI-16019 35.1 + + 7.0E-09 W.B. N.B. KZ52 ADI-16031 122.0 - - 1.1E-09 1.2E-09 N.B. KZ52 ADI-16039 105.8 + + 13.23 26.46 4.1E-09 5.0E-09 N.B. KZ52 ADI-16047 14.0 + - 3.51 4.2E-09 6.8E-09 N.B. KZ52 KZ52 IgG 5.0 + + 0.31 0.625 2.20E-09 2.10E-09 KZ52 ADI-15979 66.5 - - 6.2E-09 N.B. N.B. Mucin-like domainADI-16035 112.4 - - 5.1E-09 N.B. N.B. Mucin-like domainADI-15751 48.1 + + W.B. 2.0E-09 3.2E-10 UndefinedADI-15765 24.6 + + 0.38 1.54 3.0E-09 1.2E-09 3.3E-10 UndefinedADI-15778 82.1 - - W.B. 1.1E-08 4.6E-10 UndefinedADI-15808 23.4 - - 6.5E-09 3.3E-09 W.B UndefinedADI-15816 29.9 - - 6.0E-09 3.3E-09 N.B. UndefinedADI-15836 14.6 - - W.B. 3.2E-09 6.1E-10 UndefinedADI-15846 14.6 - - W.B. W.B. 1.8E-09 UndefinedADI-15903 32.7 + + ≤0.03 1.02 W.B. 2.7E-09 2.4E-10 UndefinedADI-15943 95.9 + + 6 3.6E-09 W.B. N.B. UndefinedADI-15944 6.8 N.D. N.D. W.B. 6.3E-09 3.4E-10 UndefinedADI-15959 6.1 + + 0.38 1.51 4.6E-09 9.9E-09 5.9E-10 UndefinedADI-15960 56.3 + + 0.05 0.88 5.6E-09 4.4E-09 4.3E-10 UndefinedADI-15970 49.2 + + W.B. 2.6E-09 3.8E-10 UndefinedADI-15971 18.2 + - 3.9E-09 5.6E-09 N.B. UndefinedADI-15980 27.9 + - 3.1E-09 1.7E-08 W.B. UndefinedADI-15986 27.6 + - 8.5E-09 2.7E-09 3.2E-10 UndefinedADI-16041 4.9 - - 1.3E-08 9.2E-09 5.1E-09 UndefinedADI-16042 22.0 + + 0.69 5.51 W.B. W.B. 6.5E-10 UndefinedADI-16043 6.9 - - W.B. N.B. 3.1E-09 UndefinedADI-16059 89.3 - - W.B. 3.5E-09 4.8E-10 Undefined

* N.D., not done; N.B., non-binder; W.B., weak binder. IgG KDs were calculated for MAbs with ForteBio binding responses >0.1 nm. MAbs with ForteBio binding responses <0.05 nm are designated as N.B.; MAbs with ForteBio binding responses between 0.05 and 0.1 nm are designated as W.B.

Table S6. Therapeutic efficacy of mAbs in a mouse model of EBOV infection.

Treatmentgroup Dose(µg) Timeoftreatment(dayspost-infection)

No.survivors/total Survival(%) Averageweightloss(%)*

P value,comparedwithnegativecontrol

mAbcompetitiongroup

PBS N/A 2 2/10 20% 8.8 N/A N/A2G4 100 2 4/10 40% 7.2 0.095 KZ52competitor

ADI-15956 100 2 7/10 70% 8.6 0.008 HR2ADI-16061 100 2 7/10 70% 9.1 0.008 HR2ADI-15974 100 2 8/10 80% 8.0 0.002 HR2ADI-15758 100 2 8/10 80% 9.8 0.009 HR2ADI-15999 100 2 10/10 100% 8.1 <0.0001 HR2ADI-15820 100 2 6/10 60% 9.9 0.026 HR2ADI-15848 100 2 7/10 70% 8.2 0.008 HR2ADI-15960 100 2 5/10 50% 15.4 0.073 UndefinedADI-15903 100 2 4/10 40% 8.4 0.079 UndefinedADI-15959 100 2 5/10 50% 8.4 0.040 UndefinedADI-15765 100 2 4/10 40% 5.9 0.102 UndefinedADI-15818 100 2 3/10 30% 13.8 0.164 KZ52competitorADI-15878 100 2 8/10 80% 10.4 0.005 KZ52competitorADI-15734 100 2 6/10 60% 7.3 0.026 KZ52competitorADI-15784 100 2 8/10 80% 9.1 0.002 KZ52competitorADI-15772 100 2 7/10 70% 11.8 0.011 KZ52competitorADI-15742 100 2 10/10 100% 10.5 0.0003 KZ52competitorADI-15731 100 2 4/10 40% 9.2 0.059 13C6competitorADI-15932 100 2 4/10 40% 12.1 0.139 13C6competitorADI-15940 100 2 4/10 40% 11.0 0.059 13C6competitorADI-15744 100 2 4/10 40% 12.3 0.095 13C6competitorADI-16037 100 2 8/10 80% 7.0 0.005 13C6competitorADI-16044 100 2 2/10 20% 9.9 0.263 13C6competitorADI-15817 100 2 4/10 40% 9.9 0.095 13C6competitor

*Averageweightchangefromthepreinjectionbaselinetothepeakofclinicaldisease.Micewereweighedasgroups.

Table S7. GenBank accession numbers for antibody gene sequences.Clonename VH VLADI-15731 KU602083 KU602084ADI-15732 KU602085 KU602086ADI-15733 KU602087 KU602088ADI-15734 KU602089 KU602090ADI-15735 KU602091 KU602092ADI-15736 KU602093 KU602094ADI-15737 KU602095 KU602096ADI-15738 KU602097 KU602098ADI-15739 KU602099 KU602100ADI-15740 KU602101 KU602102ADI-15741 KU602103 KU602104ADI-15742 KU602105 KU602106ADI-15743 KU602107 KU602108ADI-15744 KU602109 KU602110ADI-15745 KU602111 KU602112ADI-15746 KU602113 KU602114ADI-15747 KU602115 KU602116ADI-15748 KU602117 KU602118ADI-15749 KU602119 KU602120ADI-15750 KU602121 KU602122ADI-15751 KU602123 KU602124ADI-15752 KU602125 KU602126ADI-15753 KU602127 KU602128ADI-15754 KU602129 KU602130ADI-15755 KU602131 KU602132ADI-15756 KU602133 KU602134ADI-15757 KU602135 KU602136ADI-15758 KU602137 KU602138ADI-15759 KU602139 KU602140ADI-15760 KU602141 KU602142ADI-15761 KU602143 KU602144ADI-15762 KU602145 KU602146ADI-15763 KU602147 KU602148ADI-15764 KU602149 KU602150ADI-15765 KU602151 KU602152ADI-15766 KU602153 KU602154ADI-15767 KU602155 KU602156ADI-15768 KU602157 KU602158ADI-15769 KU602159 KU602160ADI-15771 KU602161 KU602162ADI-15772 KU602163 KU602164ADI-15773 KU602165 KU602166ADI-15774 KU602167 KU602168ADI-15775 KU602169 KU602170ADI-15777 KU602171 KU602172ADI-15778 KU602173 KU602174ADI-15779 KU602175 KU602176ADI-15780 KU602177 KU602178ADI-15781 KU602179 KU602180ADI-15782 KU602181 KU602182ADI-15783 KU602183 KU602184ADI-15784 KU602185 KU602186ADI-15785 KU602187 KU602188ADI-15786 KU602189 KU602190ADI-15787 KU602191 KU602192ADI-15788 KU602193 KU602194ADI-15789 KU602195 KU602196ADI-15791 KU602197 KU602198ADI-15792 KU602199 KU602200ADI-15793 KU602201 KU602202ADI-15794 KU602203 KU602204ADI-15795 KU602205 KU602206ADI-15796 KU602207 KU602208ADI-15797 KU602209 KU602210ADI-15798 KU602211 KU602212ADI-15799 KU602213 KU602214ADI-15800 KU602215 KU602216ADI-15801 KU602217 KU602218ADI-15802 KU602219 KU602220ADI-15803 KU602221 KU602222ADI-15804 KU602223 KU602224ADI-15805 KU602225 KU602226ADI-15806 KU602227 KU602228ADI-15807 KU602229 KU602230ADI-15808 KU602231 KU602232ADI-15809 KU602233 KU602234ADI-15810 KU602235 KU602236ADI-15811 KU602237 KU602238ADI-15812 KU602239 KU602240ADI-15813 KU602241 KU602242ADI-15814 KU602243 KU602244ADI-15815 KU602245 KU602246ADI-15816 KU602247 KU602248ADI-15817 KU602249 KU602250ADI-15818 KU602251 KU602252ADI-15819 KU602253 KU602254ADI-15820 KU602255 KU602256ADI-15821 KU602257 KU602258ADI-15822 KU602259 KU602260ADI-15823 KU602261 KU602262ADI-15824 KU602263 KU602264ADI-15825 KU602265 KU602266ADI-15826 KU602267 KU602268ADI-15827 KU602269 KU602270ADI-15828 KU602271 KU602272ADI-15829 KU602273 KU602274ADI-15830 KU602275 KU602276ADI-15831 KU602277 KU602278ADI-15832 KU602279 KU602280ADI-15833 KU602281 KU602282ADI-15834 KU602283 KU602284ADI-15835 KU602285 KU602286ADI-15836 KU602287 KU602288ADI-15837 KU602289 KU602290ADI-15839 KU602291 KU602292ADI-15841 KU602293 KU602294ADI-15842 KU602295 KU602296ADI-15843 KU602297 KU602298ADI-15844 KU602299 KU602300

GenBankaccessionnumbersClonename VH VL

GenBankaccessionnumbers

ADI-15845 KU602301 KU602302ADI-15846 KU602303 KU602304ADI-15847 KU602305 KU602306ADI-15848 KU602307 KU602308ADI-15849 KU602309 KU602310ADI-15850 KU602311 KU602312ADI-15851 KU602313 KU602314ADI-15852 KU602315 KU602316ADI-15853 KU602317 KU602318ADI-15854 KU602319 KU602320ADI-15855 KU602321 KU602322ADI-15856 KU602323 KU602324ADI-15858 KU602325 KU602326ADI-15859 KU602327 KU602328ADI-15860 KU602329 KU602330ADI-15861 KU602331 KU602332ADI-15862 KU602333 KU602334ADI-15863 KU602335 KU602336ADI-15864 KU602337 KU602338ADI-15865 KU602339 KU602340ADI-15866 KU602341 KU602342ADI-15867 KU602343 KU602344ADI-15868 KU602345 KU602346ADI-15869 KU602347 KU602348ADI-15870 KU602349 KU602350ADI-15871 KU602351 KU602352ADI-15872 KU602353 KU602354ADI-15873 KU602355 KU602356ADI-15874 KU602357 KU602358ADI-15875 KU602359 KU602360ADI-15876 KU602361 KU602362ADI-15877 KU602363 KU602364ADI-15878 KU602365 KU602366ADI-15879 KU602367 KU602368ADI-15880 KU602369 KU602370ADI-15881 KU602371 KU602372ADI-15882 KU602373 KU602374ADI-15883 KU602375 KU602376ADI-15884 KU602377 KU602378ADI-15885 KU602379 KU602380ADI-15886 KU602381 KU602382ADI-15887 KU602383 KU602384ADI-15888 KU602385 KU602386ADI-15889 KU602387 KU602388ADI-15890 KU602389 KU602390ADI-15891 KU602391 KU602392ADI-15892 KU602393 KU602394ADI-15893 KU602395 KU602396ADI-15894 KU602397 KU602398ADI-15895 KU602399 KU602400ADI-15896 KU602401 KU602402ADI-15897 KU602403 KU602404ADI-15898 KU602405 KU602406ADI-15899 KU602407 KU602408ADI-15900 KU602409 KU602410ADI-15901 KU602411 KU602412ADI-15902 KU602413 KU602414ADI-15903 KU602415 KU602416ADI-15904 KU602417 KU602418ADI-15906 KU602419 KU602420ADI-15907 KU602421 KU602422ADI-15908 KU602423 KU602424ADI-15909 KU602425 KU602426ADI-15910 KU602427 KU602428ADI-15911 KU602429 KU602430ADI-15912 KU602431 KU602432ADI-15913 KU602433 KU602434ADI-15914 KU602435 KU602436ADI-15915 KU602437 KU602438ADI-15916 KU602439 KU602440ADI-15917 KU602441 KU602442ADI-15918 KU602443 KU602444ADI-15919 KU602445 KU602446ADI-15920 KU602447 KU602448ADI-15921 KU602449 KU602450ADI-15922 KU602451 KU602452ADI-15923 KU602453 KU602454ADI-15924 KU602455 KU602456ADI-15925 KU602457 KU602458ADI-15926 KU602459 KU602460ADI-15927 KU602461 KU602462ADI-15928 KU602463 KU602464ADI-15929 KU602465 KU602466ADI-15930 KU602467 KU602468ADI-15931 KU602469 KU602470ADI-15932 KU602471 KU602472ADI-15933 KU602473 KU602474ADI-15934 KU602475 KU602476ADI-15935 KU602477 KU602478ADI-15936 KU602479 KU602480ADI-15937 KU602481 KU602482ADI-15938 KU602483 KU602484ADI-15939 KU602485 KU602486ADI-15940 KU602487 KU602488ADI-15941 KU602489 KU602490ADI-15942 KU602491 KU602492ADI-15943 KU602493 KU602494ADI-15944 KU602495 KU602496ADI-15945 KU602497 KU602498ADI-15946 KU602499 KU602500ADI-15947 KU602501 KU602502ADI-15948 KU602503 KU602504ADI-15949 KU602505 KU602506ADI-15950 KU602507 KU602508ADI-15951 KU602509 KU602510ADI-15952 KU602511 KU602512ADI-15953 KU602513 KU602514ADI-15954 KU602515 KU602516ADI-15955 KU602517 KU602518

Clonename VH VLGenBankaccessionnumbers

ADI-15956 KU602519 KU602520ADI-15957 KU602521 KU602522ADI-15958 KU602523 KU602524ADI-15959 KU602525 KU602526ADI-15960 KU602527 KU602528ADI-15961 KU602529 KU602530ADI-15962 KU602531 KU602532ADI-15963 KU602533 KU602534ADI-15964 KU602535 KU602536ADI-15965 KU602537 KU602538ADI-15966 KU602539 KU602540ADI-15967 KU602541 KU602542ADI-15968 KU602543 KU602544ADI-15969 KU602545 KU602546ADI-15970 KU602547 KU602548ADI-15971 KU602549 KU602550ADI-15972 KU602551 KU602552ADI-15973 KU602553 KU602554ADI-15974 KU602555 KU602556ADI-15975 KU602557 KU602558ADI-15976 KU602559 KU602560ADI-15977 KU602561 KU602562ADI-15978 KU602563 KU602564ADI-15979 KU602565 KU602566ADI-15980 KU602567 KU602568ADI-15981 KU602569 KU602570ADI-15982 KU602571 KU602572ADI-15983 KU602573 KU602574ADI-15984 KU602575 KU602576ADI-15985 KU602577 KU602578ADI-15986 KU602579 KU602580ADI-15987 KU602581 KU602582ADI-15988 KU602583 KU602584ADI-15989 KU602585 KU602586ADI-15990 KU602587 KU602588ADI-15991 KU602589 KU602590ADI-15992 KU602591 KU602592ADI-15993 KU602593 KU602594ADI-15994 KU602595 KU602596ADI-15995 KU602597 KU602598ADI-15996 KU602599 KU602600ADI-15997 KU602601 KU602602ADI-15998 KU602603 KU602604ADI-15999 KU602605 KU602606ADI-16000 KU602607 KU602608ADI-16001 KU602609 KU602610ADI-16003 KU602611 KU602612ADI-16005 KU602613 KU602614ADI-16006 KU602615 KU602616ADI-16007 KU602617 KU602618ADI-16008 KU602619 KU602620ADI-16009 KU602621 KU602622ADI-16010 KU602623 KU602624ADI-16011 KU602625 KU602626ADI-16012 KU602627 KU602628ADI-16013 KU602629 KU602630ADI-16015 KU602631 KU602632ADI-16016 KU602633 KU602634ADI-16017 KU602635 KU602636ADI-16018 KU602637 KU602638ADI-16019 KU602639 KU602640ADI-16020 KU602641 KU602642ADI-16021 KU602643 KU602644ADI-16022 KU602645 KU602646ADI-16024 KU602647 KU602648ADI-16025 KU602649 KU602650ADI-16026 KU602651 KU602652ADI-16027 KU602653 KU602654ADI-16028 KU602655 KU602656ADI-16029 KU602657 KU602658ADI-16030 KU602659 KU602660ADI-16031 KU602661 KU602662ADI-16032 KU602663 KU602664ADI-16033 KU602665 KU602666ADI-16034 KU602667 KU602668ADI-16035 KU602669 KU602670ADI-16036 KU602671 KU602672ADI-16037 KU602673 KU602674ADI-16038 KU602675 KU602676ADI-16039 KU602677 KU602678ADI-16040 KU602679 KU602680ADI-16041 KU602681 KU602682ADI-16042 KU602683 KU602684ADI-16043 KU602685 KU602686ADI-16044 KU602687 KU602688ADI-16045 KU602689 KU602690ADI-16046 KU602691 KU602692ADI-16047 KU602693 KU602694ADI-16048 KU602695 KU602696ADI-16049 KU602697 KU602698ADI-16050 KU602699 KU602700ADI-16051 KU602701 KU602702ADI-16052 KU602703 KU602704ADI-16053 KU602705 KU602706ADI-16054 KU602707 KU602708ADI-16055 KU602709 KU602710ADI-16056 KU602711 KU602712ADI-16058 KU602713 KU602714ADI-16059 KU602715 KU602716ADI-16060 KU602717 KU602718ADI-16061 KU602719 KU602720ADI-16062 KU602721 KU602722ADI-16063 KU602723 KU602724

1

REFERENCES 1. P. Roddy, A call to action to enhance filovirus disease outbreak preparedness and response.

Viruses 6, 3699–3718 (2014). Medline doi:10.3390/v6103699

2. A. Marzi, S. J. Robertson, E. Haddock, F. Feldmann, P. W. Hanley, D. P. Scott, J. E. Strong, G. Kobinger, S. M. Best, H. Feldmann, VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349, 739–742 (2015). Medline doi:10.1126/science.aab3920

3. X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando, J. B. Alimonti, H. Fausther-Bovendo, H. Wei, J. Aviles, E. Hiatt, A. Johnson, J. Morton, K. Swope, O. Bohorov, N. Bohorova, C. Goodman, D. Kim, M. H. Pauly, J. Velasco, J. Pettitt, G. G. Olinger, K. Whaley, B. Xu, J. E. Strong, L. Zeitlin, G. P. Kobinger, Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47–53 (2014). Medline

4. C. D. Murin, M. L. Fusco, Z. A. Bornholdt, X. Qiu, G. G. Olinger, L. Zeitlin, G. P. Kobinger, A. B. Ward, E. O. Saphire, Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl. Acad. Sci. U.S.A. 111, 17182–17187 (2014). Medline doi:10.1073/pnas.1414164111

5. J. M. Dias, A. I. Kuehne, D. M. Abelson, S. Bale, A. C. Wong, P. Halfmann, M. A. Muhammad, M. L. Fusco, S. E. Zak, E. Kang, Y. Kawaoka, K. Chandran, J. M. Dye, E. O. Saphire, A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18, 1424–1427 (2011). Medline doi:10.1038/nsmb.2150

6. J. E. Lee, M. L. Fusco, A. J. Hessell, W. B. Oswald, D. R. Burton, E. O. Saphire, Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177–182 (2008). Medline doi:10.1038/nature07082

7. G. G. Olinger Jr., J. Pettitt, D. Kim, C. Working, O. Bohorov, B. Bratcher, E. Hiatt, S. D. Hume, A. K. Johnson, J. Morton, M. Pauly, K. J. Whaley, C. M. Lear, J. E. Biggins, C. Scully, L. Hensley, L. Zeitlin, Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 109, 18030–18035 (2012). Medline doi:10.1073/pnas.1213709109

8. T. Maruyama, L. L. Rodriguez, P. B. Jahrling, A. Sanchez, A. S. Khan, S. T. Nichol, C. J. Peters, P. W. Parren, D. R. Burton, Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73, 6024–6030 (1999). Medline

9. W. B. Oswald, T. W. Geisbert, K. J. Davis, J. B. Geisbert, N. J. Sullivan, P. B. Jahrling, P. W. Parren, D. R. Burton, Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLOS Pathog. 3, e9 (2007). Medline doi:10.1371/journal.ppat.0030009

10. A. I. Flyak, X. Shen, C. D. Murin, H. L. Turner, J. A. David, M. L. Fusco, R. Lampley, N. Kose, P. A. Ilinykh, N. Kuzmina, A. Branchizio, H. King, L. Brown, C. Bryan, E. Davidson, B. J. Doranz, J. C. Slaughter, G. Sapparapu, C. Klages, T. G. Ksiazek, E. O. Saphire, A. B. Ward, A. Bukreyev, J. E. Crowe Jr., Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebolavirus infection. Cell 164, 392–405 (2016). Medline doi:10.1016/j.cell.2015.12.022

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25271875&dopt=Abstract

http://dx.doi.org/10.3390/v6103699



http://dx.doi.org/10.1126/science.aab3920



http://dx.doi.org/10.1073/pnas.1414164111


http://dx.doi.org/10.1038/nsmb.2150


http://dx.doi.org/10.1038/nature07082


http://dx.doi.org/10.1073/pnas.1213709109



http://dx.doi.org/10.1371/journal.ppat.0030009


http://dx.doi.org/10.1016/j.cell.2015.12.022

2

11. J. F. Scheid, H. Mouquet, N. Feldhahn, M. S. Seaman, K. Velinzon, J. Pietzsch, R. G. Ott, R. M. Anthony, H. Zebroski, A. Hurley, A. Phogat, B. Chakrabarti, Y. Li, M. Connors, F. Pereyra, B. D. Walker, H. Wardemann, D. Ho, R. T. Wyatt, J. R. Mascola, J. V. Ravetch, M. C. Nussenzweig, Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636–640 (2009). Medline

12. M. Beltramello, K. L. Williams, C. P. Simmons, A. Macagno, L. Simonelli, N. T. Quyen, S. Sukupolvi-Petty, E. Navarro-Sanchez, P. R. Young, A. M. de Silva, F. A. Rey, L. Varani, S. S. Whitehead, M. S. Diamond, E. Harris, A. Lanzavecchia, F. Sallusto, The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271–283 (2010). Medline doi:10.1016/j.chom.2010.08.007

13. Y. Xu, W. Roach, T. Sun, T. Jain, B. Prinz, T. Y. Yu, J. Torrey, J. Thomas, P. Bobrowicz, M. Vásquez, K. D. Wittrup, E. Krauland, Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: A FACS-based, high-throughput selection and analytical tool. Protein Eng. Des. Sel. 26, 663–670 (2013). Medline doi:10.1093/protein/gzt047

14. J. Wrammert, K. Smith, J. Miller, W. A. Langley, K. Kokko, C. Larsen, N. Y. Zheng, I. Mays, L. Garman, C. Helms, J. James, G. M. Air, J. D. Capra, R. Ahmed, P. C. Wilson, Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667–671 (2008). Medline doi:10.1038/nature06890

15. S. D. Boyd, B. A. Gaëta, K. J. Jackson, A. Z. Fire, E. L. Marshall, J. D. Merker, J. M. Maniar, L. N. Zhang, B. Sahaf, C. D. Jones, B. B. Simen, B. Hanczaruk, K. D. Nguyen, K. C. Nadeau, M. Egholm, D. B. Miklos, J. L. Zehnder, A. M. Collins, Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. J. Immunol. 184, 6986–6992 (2010). Medline doi:10.4049/jimmunol.1000445

16. K. J. Jackson, Y. Wang, B. A. Gaeta, W. Pomat, P. Siba, J. Rimmer, W. A. Sewell, A. M. Collins, Divergent human populations show extensive shared IGK rearrangements in peripheral blood B cells. Immunogenetics 64, 3–14 (2012). Medline doi:10.1007/s00251-011-0559-z

17. A. Sanchez, S. G. Trappier, B. W. Mahy, C. J. Peters, S. T. Nichol, The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. U.S.A. 93, 3602–3607 (1996). Medline doi:10.1073/pnas.93.8.3602

18. S. K. Gire, A. Goba, K. G. Andersen, R. S. Sealfon, D. J. Park, L. Kanneh, S. Jalloh, M. Momoh, M. Fullah, G. Dudas, S. Wohl, L. M. Moses, N. L. Yozwiak, S. Winnicki, C. B. Matranga, C. M. Malboeuf, J. Qu, A. D. Gladden, S. F. Schaffner, X. Yang, P. P. Jiang, M. Nekoui, A. Colubri, M. R. Coomber, M. Fonnie, A. Moigboi, M. Gbakie, F. K. Kamara, V. Tucker, E. Konuwa, S. Saffa, J. Sellu, A. A. Jalloh, A. Kovoma, J. Koninga, I. Mustapha, K. Kargbo, M. Foday, M. Yillah, F. Kanneh, W. Robert, J. L. Massally, S. B. Chapman, J. Bochicchio, C. Murphy, C. Nusbaum, S. Young, B. W. Birren, D. S. Grant, J. S. Scheiffelin, E. S. Lander, C. Happi, S. M. Gevao, A. Gnirke, A. Rambaut, R. F. Garry, S. H. Khan, P. C. Sabeti, Genomic surveillance elucidates Ebola virus origin




http://dx.doi.org/10.1016/j.chom.2010.08.007


http://dx.doi.org/10.1093/protein/gzt047


http://dx.doi.org/10.1038/nature06890


http://dx.doi.org/10.4049/jimmunol.1000445


http://dx.doi.org/10.1007/s00251-011-0559-z

http://dx.doi.org/10.1007/s00251-011-0559-z


http://dx.doi.org/10.1073/pnas.93.8.3602

3

and transmission during the 2014 outbreak. Science 345, 1369–1372 (2014). Medline doi:10.1126/science.1259657

19. G. S. Mohan, W. Li, L. Ye, R. W. Compans, C. Yang, Antigenic subversion: A novel mechanism of host immune evasion by Ebola virus. PLOS Pathog. 8, e1003065 (2012). Medline doi:10.1371/journal.ppat.1003065

20. D. R. Bowley, A. F. Labrijn, M. B. Zwick, D. R. Burton, Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng. Des. Sel. 20, 81–90 (2007). Medline doi:10.1093/protein/gzl057

21. J. Audet, G. Wong, H. Wang, G. Lu, G. F. Gao, G. Kobinger, X. Qiu, Molecular characterization of the monoclonal antibodies composing ZMAb: A protective cocktail against Ebola virus. Sci Rep 4, 6881 (2014). Medline doi:10.1038/srep06881

22. W. Weissenhorn, A. Carfí, K. H. Lee, J. J. Skehel, D. C. Wiley, Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2, 605–616 (1998). Medline doi:10.1016/S1097-2765(00)80159-8

23. M. Bray, K. Davis, T. Geisbert, C. Schmaljohn, J. Huggins, A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179 (Suppl 1), S248–S258 (1999). Medline doi:10.1086/514292

24. X. Qiu et al., Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLOS Negl. Trop. Dis. 6, e1575 (2012).

25. J. R. Kugelman et al., Emergence of Ebola virus escape variants in infected nonhuman primates treated with the MB-003 antibody cocktail. Cell Rep. (2015).

26. X. Qiu, J. Audet, G. Wong, S. Pillet, A. Bello, T. Cabral, J. E. Strong, F. Plummer, C. R. Corbett, J. B. Alimonti, G. P. Kobinger, Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4, 138ra81 (2012). Medline doi:10.1126/scitranslmed.3003876

27. T. Hashiguchi, M. L. Fusco, Z. A. Bornholdt, J. E. Lee, A. I. Flyak, R. Matsuoka, D. Kohda, Y. Yanagi, M. Hammel, J. E. Crowe Jr., E. O. Saphire, Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160, 904–912 (2015). Medline doi:10.1016/j.cell.2015.01.041

28. Y. Shen, J. Maupetit, P. Derreumaux, P. Tufféry, Improved PEP-FOLD approach for peptide and miniprotein structure prediction. J. Chem. Theory Comput. 10, 4745–4758 (2014). Medline doi:10.1021/ct500592m

29. S. Lyskov, F. C. Chou, S. Ó. Conchúir, B. S. Der, K. Drew, D. Kuroda, J. Xu, B. D. Weitzner, P. D. Renfrew, P. Sripakdeevong, B. Borgo, J. J. Havranek, B. Kuhlman, T. Kortemme, R. Bonneau, J. J. Gray, R. Das, Serverification of molecular modeling applications: The Rosetta Online Server that Includes Everyone (ROSIE). PLOS One 8, e63906 (2013). Medline doi:10.1371/journal.pone.0063906

30. A. Sivasubramanian, A. Sircar, S. Chaudhury, J. J. Gray, Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking. Proteins 74, 497–514 (2009). Medline doi:10.1002/prot.22309


http://dx.doi.org/10.1126/science.1259657



http://dx.doi.org/10.1371/journal.ppat.1003065


http://dx.doi.org/10.1093/protein/gzl057


http://dx.doi.org/10.1038/srep06881


http://dx.doi.org/10.1016/S1097-2765(00)80159-8


http://dx.doi.org/10.1086/514292



http://dx.doi.org/10.1126/scitranslmed.3003876


http://dx.doi.org/10.1016/j.cell.2015.01.041



http://dx.doi.org/10.1021/ct500592m


http://dx.doi.org/10.1371/journal.pone.0063906


http://dx.doi.org/10.1002/prot.22309

4

31. T. Tiller, E. Meffre, S. Yurasov, M. Tsuiji, M. C. Nussenzweig, H. Wardemann, Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112–124 (2008). Medline doi:10.1016/j.jim.2007.09.017

32. J. S. Swers, B. A. Kellogg, K. D. Wittrup, Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Res. 32, e36 (2004). Medline doi:10.1093/nar/gnh030

33. R. D. Gietz, R. H. Schiestl, High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2, 31–34 (2007). Medline doi:10.1038/nprot.2007.13

34. S. P. Honnold, R. R. Bakken, D. Fisher, C. M. Lind, J. W. Cohen, L. T. Eccleston, K. B. Spurgers, R. K. Maheshwari, P. J. Glass, Second generation inactivated eastern equine encephalitis virus vaccine candidates protect mice against a lethal aerosol challenge. PLOS ONE 9, e104708 (2014). Medline doi:10.1371/journal.pone.0104708

35. C. Suloway, J. Pulokas, D. Fellmann, A. Cheng, F. Guerra, J. Quispe, S. Stagg, C. S. Potter, B. Carragher, Automated molecular microscopy: The new Leginon system. J. Struct. Biol. 151, 41–60 (2005). Medline doi:10.1016/j.jsb.2005.03.010

36. G. C. Lander, S. M. Stagg, N. R. Voss, A. Cheng, D. Fellmann, J. Pulokas, C. Yoshioka, C. Irving, A. Mulder, P. W. Lau, D. Lyumkis, C. S. Potter, B. Carragher, Appion: An integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95–102 (2009). Medline

37. N. R. Voss, C. K. Yoshioka, M. Radermacher, C. S. Potter, B. Carragher, DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy. J. Struct. Biol. 166, 205–213 (2009). Medline doi:10.1016/j.jsb.2009.01.004

38. G. Tang, L. Peng, P. R. Baldwin, D. S. Mann, W. Jiang, I. Rees, S. J. Ludtke, EMAN2: An extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38–46 (2007). Medline doi:10.1016/j.jsb.2006.05.009

39. T. D. Goddard, C. C. Huang, T. E. Ferrin, Visualizing density maps with UCSF Chimera. J. Struct. Biol. 157, 281–287 (2007). Medline doi:10.1016/j.jsb.2006.06.010


http://dx.doi.org/10.1016/j.jim.2007.09.017



http://dx.doi.org/10.1093/nar/gnh030


http://dx.doi.org/10.1038/nprot.2007.13


http://dx.doi.org/10.1371/journal.pone.0104708


http://dx.doi.org/10.1016/j.jsb.2005.03.010








supplementary materials figures -...

Documents